GO.ID	Term	p-Value

Topic 2

GO:0001054	RNA polymerase I activity	2.5e-07

GO:0043022	ribosome binding	4.8e-06

GO:0030515	snoRNA binding	5.0e-06

GO:0005524	ATP binding	6.1e-06

Topic 3

GO:0003713	transcription coactivator activity	7.6e-07

GO:0003730	mRNA 3’-UTR binding	4.6e-06

GO:0004843	ubiquitin-specific protease activity	7.7e-06

Topic 4

GO:0020037	heme binding	2.2e-19

O:0008395	steroid hydroxylase activity	5.9e-18

O:0019825	oxygen binding	6.5e-14

O:0005506	iron ion binding	9.2e-13

O:0004364	glutathione transferase activity	1.5e-12

O:0008392	arachidonic acid epoxygenase activity	1.9e-12

O:0005102	receptor binding	4.2e-11

GO:0004867	serine-type endopeptidase inhibitor activity	1.1e-10

GO:0009055	electron carrier activity	1.3e-10

GO:0070330	aromatase activity	2.6e-10

GO:0042803	protein homodimerization activity	7.4e-10

GO:0008201	heparin binding	1.5e-09

GO:0002020	protease binding	2.5e-08

GO:0051087	chaperone binding	6.0e-07

GO:0003988	acetyl-CoA C-acyltransferase activity	8.4e-07

GO:0016836	hydro-lyase activity	1.0e-06

GO:0004602	glutathione peroxidase activity	1.0e-06

GO:0004601	peroxidase activity	1.3e-06

GO:0030170	pyridoxal phosphate binding	1.6e-06

GO:0004029	aldehyde dehydrogenase (NAD) activity	2.4e-06

GO:0001848	complement binding	3.1e-06

GO:0016616	oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	3.2e-06

GO:0050660	flavin adenine dinucleotide binding	3.8e-06

GO:0005507	copper ion binding	4.1e-06

GO:0016709	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	5.3e-06

GO:0032403	protein complex binding	5.7e-06

GO:0051537	2 iron, 2 sulfur cluster binding	7.8e-06

GO.ID	Term	p-Value

GO:0001054	RNA polymerase I activity	2.5e-07

GO:0043022	ribosome binding	4.8e-06

GO:0030515	snoRNA binding	5.0e-06

GO:0005524	ATP binding	6.1e-06

Topic 3

GO:0003713	transcription coactivator activity	7.6e-07

GO:0003730	mRNA 3’-UTR binding	4.6e-06

GO:0004843	ubiquitin-specific protease activity	7.7e-06

Topic 4

GO:0020037	heme binding	2.2e-19

O:0008395	steroid hydroxylase activity	5.9e-18

O:0019825	oxygen binding	6.5e-14

O:0005506	iron ion binding	9.2e-13

O:0004364	glutathione transferase activity	1.5e-12

O:0008392	arachidonic acid epoxygenase activity	1.9e-12

O:0005102	receptor binding	4.2e-11

GO:0004867	serine-type endopeptidase inhibitor activity	1.1e-10

GO:0009055	electron carrier activity	1.3e-10

GO:0070330	aromatase activity	2.6e-10

GO:0042803	protein homodimerization activity	7.4e-10

GO:0008201	heparin binding	1.5e-09

GO:0002020	protease binding	2.5e-08

GO:0051087	chaperone binding	6.0e-07

GO:0003988	acetyl-CoA C-acyltransferase activity	8.4e-07

GO:0016836	hydro-lyase activity	1.0e-06

GO:0004602	glutathione peroxidase activity	1.0e-06

GO:0004601	peroxidase activity	1.3e-06

GO:0030170	pyridoxal phosphate binding	1.6e-06

GO:0004029	aldehyde dehydrogenase (NAD) activity	2.4e-06

GO:0001848	complement binding	3.1e-06

GO:0016616	oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	3.2e-06

GO:0050660	flavin adenine dinucleotide binding	3.8e-06

GO:0005507	copper ion binding	4.1e-06

GO:0016709	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	5.3e-06

GO:0032403	protein complex binding	5.7e-06

GO:0051537	2 iron, 2 sulfur cluster binding	7.8e-06


Characteristics	Total (n, %)

Number	73

Age (years)	67.0 (SD 14.1)

Sex male	52 (71.2)

Admission NIHSS score	9.3 (SD 3.2)

Admission GCS score	5.6 (SD 2.0)

Smoking	30 (41.1)

Excess alcohol consumption	22 (30.1)

Pre-existing illnesses

 Hypertension	53 (72.6)

 Diabetes	36 (49.3)

 Coronary heart disease	14 (19.2)

 Liver disease (except for hepatic cirrhosis)	0 (0)

 Kidney disease	2 (2.7)

Chest X ray	73 (100)

Chest CT	58 (79.5)

 GGOs	40/58 (69.0)

 Consolidation opacities	31/58 (53.4)

 Pleural effusions	14/58 (24.1)

 Air bronchogram	11/58 (19.0)

Tachypnea (RR ≥ 25 breaths/min)	67 (91.8)

Fever (T ≥ 37.5 °C)	43 (58.9)

PaO2/FiO2 (mmHg)	143.5 (SD 59.0)

APACHE II score	28.2 (SD 10.4)

pH value	7.38 (SD 0.57)

Acidosis (pH < 7.35)	11 (15.1)

Albumin (g/L)	26.1 (SD 9.2)

Treatment

Corticosteroids	47 (64.4)

 No respiratory response	16/47 (34.0)

 Respiratory response	31/47 (66.0)

Ventilatory support	63 (86.3)

 Non-invasive ventilation alone	14/63 (22.2)

 Non-invasive ventilation followed by intubation	16/63 (25.4)

 First line invasive ventilation	33/63 (52.4)

Time from diagnosis to corticosteroids (days)	6.5 (SD 3.5)

Outcomes

 Duration of IMV (days)	8.5 (SD 5.5)

 Hospital LOS (days)	23.0 (SD 7.0)

 Hospital mortality	29 (39.7)


Hit rate (confirmed hits with selectivity over mammalian cell cytotoxicity)	G+ve	G-ve	Fungi

CO-ADD academic hit rate	0.66%	0.21%	0.98%

Commercial hit rate	0.03%	0.008%	ND

Hit rate (confirmed hits with selectivity over mammalian cell cytotoxicity)	G+ve	G-ve	Fungi

Commercial hit rate	0.03%	0.008%	ND


Molecular subtypes	Immunohistochemical characterization

Luminal A	ER + and/or PR+, HER2- CK8/18+

Luminal B	ER + and/or PR+, HER2+, CK8/18+

HER2+	ER-, PR-, HER2+

basal-like	ER-, PR-, HER2- and CK 5/6+, HER1+ and/or CK14+

Unclassified	ER-, PR-, HER2-, CK 5/6-, HER1- and CK14-

Molecular subtypes

Luminal A

Luminal B

HER2+

basal-like

Unclassified

Immunohistochemical characterization

ER + and/or PR+, HER2- CK8/18+

ER + and/or PR+, HER2+, CK8/18+

ER-, PR-, HER2+

ER-, PR-, HER2- and CK 5/6+, HER1+ and/or CK14+

ER-, PR-, HER2-, CK 5/6-, HER1- and CK14-


DNA adduct levels/HPV infection	Protein expression	p-value

Negative (%)	Positive (%)

XRCC3


Control group

Score	2 weeks	14 weeks	26 weeks

Total	-0.06	-0.05	+0.01

Symptom domain	-0.21	-0.14	-0.11

Mental domain	0.0	0.0	0.0

Function domain	+0.05	+0.02	+0.14

Control group

Score

Total

Symptom domain

Mental domain

Function domain


Jurisdiction	Health policy change in studied period	Cost sharing mechanism	References

Outpatient/Inpatient services	Pharmaceuticals

1 Czech Rep	Introduction of formal fees	Until the end of 2007, outpatient and inpatient services were free of charge. Since 2008, formal OOPs exists; a flat fee of 30 CZK (€1.2) per doctor visit, 60 CZK (€2.4) per hospital day as well as spa hotels, 90 CZK (€3.6) per ambulatory visit outside of working hours. An annual ceiling of CZK 5000 (€200) for expenses related to doctor visits and drug costs was introduced. Since 2009, a new ceiling of CZK 2500 (€100) for those below 18 and above 65 was launched. A flat fee per doctor visit for children was eliminated. Since 2012, a flat fee for hospital and spa stay was reduced to 100 CZK per stay (€3.92 EUR). The dental care is paid by OOPs too. Some groups such as poor, pregnant woman, chronically ill children, patients with infectious diseases are exempted from formal OOPs.(Exchange rate used; 1 EUR = 250 CZK)	Until 2008, some form of co-payments existed. A prescription fee of 30 CZK (1.18 EUR) per item was introduced in 2008. Since 2009, a difference between actual and reimbursement price is paid out of pocket if it is higher than prescription fee.	[3, 22]

2 Estonia	Introduction of formal fees	Since 1995, a fee of €0.30 (EEK 5) per first initial outpatient consultation at public hospitals and/or health centers exists, a free price setting for specialists. Since 2002, no fees for GP visits (except for home GP visit which is €3.2) but ambulatory specialist care at maximum fee of €3.20 (EEK 50) unless a referral within the same institution or specialty is granted. Hospital fees are implemented at 1.6 EUR per day, for up to 10 days per episode of illness. Some exemptions for children, pregnant woman and emergency care apply. (Exchange rate used; 1 EUR = 15.6 EEK)	Co-payment consist of a prescription fee of €1.30 plus the difference between actual price and reimbursement level. The general reimbursement rate is 50 % of the pharmaceutical price up to a maximum reimbursement of €12.00 (EEK 200) per prescription. The reimbursement of drugs for chronic disease, children, seniors and disabled is higher, up to 100 % .	[40, 41]

3 Hungary	Introduction of formal fees	To limited extend, some form of copayments already existed since 1989 (medical devices, spas, specialist treatment outside of standard patient’s pathway etc.). Since 2007 formal co-payments were introduced; app €1 per ambulatory visit and per hospital day. After the referendum held in 2008, they were abolished.	Since 2007 reimbursement rates have been decreased from 50 to 25 %; from 70 to 55 %; and from 90 to 85 %. For drugs with a special reimbursement of 90 %, three levels of coverage was established: 50, 70 and 90 %. For drugs fully reimbursed, a minimum €1 (300 HUF) fee per prescription was introduced. For special attentionpatients eligible for free of charge drugs, a monthly limit of 40 EUR was established. OOPs apply above that sum. Eligibility for special attention is defined by GP. (Exchange rate used; 1 EUR = 250 HUF)	[21, 34]

4 Slovakia	Introduction of formal fees	The formal copayments were introduced in 2003. Since then, app. €0.66 is paid per doctor visit and app. 1.66 EUR per hospital day, app €1.99 per emergency care visit,€0.07 per km for ambulance transport and between €4.98 and 7.30 per food and accommodation in spas. In 2006, user fees for a doctor’s visit and daily hospital stay were abolished. (Exchange rate used; 1 EUR = 40.03 SKK)	Until 2003, some form of co-payments existed. Since then €0.5 EUR prescription fee has to be paid. It was reduced to €0.17in 2006. If there is a difference between the price of the drug and the reimbursement level, patient has to cover it as well.	[11, 42]


Data collection

X-ray source	PF BL-5A

Wavelength (Å)	1.0000

Space group	P41212

Unit-cell parameters (Å)	a = b = 91.3, c = 265.4

Resolution (Å)a	20.0-2.20 (2.28-2.20)

Observed reflections	689047

Unique reflections	55949

Completeness (%)a	96.5 (81.0)

Rmerge (%)a,b	9.2 (23.9)

<I>/<σ(I) > a	55.6 (11.4)

Refinement

Resolution range (Å)	20.0-2.20

Rfactor(%)c	19.2

Rfree(%)d	23.0

Protein atoms	8020

NADPH atoms	192

Water molecules	302

r.m.s deviaton from ideal

Bond lengths (Å)	0.011

Bond angles (deg.)	1.43

Ramachandran plote

Most favored regions (%)	91.7

Allowed regions (%)	8.3

Data collection

X-ray source

Wavelength (Å)

Space group

Unit-cell parameters (Å)

Resolution (Å)a

Observed reflections

Unique reflections

Completeness (%)a

Rmerge (%)a,b

/<σ(I) > a

Refinement

Resolution range (Å)

Rfactor(%)c

Rfree(%)d

Protein atoms

NADPH atoms

Water molecules

r.m.s deviaton from ideal

Bond lengths (Å)

Bond angles (deg.)

Ramachandran plote

Most favored regions (%)

Allowed regions (%)


Step	Candidate genes	Wilks’ Lambda	Exact F

			Statistic	p value

1	TNFAIP3	0.404	59.002	<0.001

2	IL-21	0.300	45.521	<0.001

Step	Candidate genes	Wilks’ Lambda	Exact F

			Statistic	p value

3	c-REL	0.261	35.809	<0.001

4	RGS1	0.235	30.143	<0.001

5	LPP	0.222	25.272	<0.001


Factors	Concepts	Health professionals’ experiences, barriers and facilitators & possible improvements with regard to:

Guideline related factors	Feasibility of the recommended guideline and the protocol derived from the guideline	- Guideline- Protocol- EHR- Consults- Collaboration with other continence professionals: Informing the woman’s GP after the consult by means of a letter, Advices for referrals, diagnostics and treatments

	Compatibility of the protocol: the extent to which the recommended protocol is practical	likewise

Individual health professional factors	Competences (=skills, attitude and knowledge) needed: the extent to which the targeted health professionals have competences they need	- Competences needed- Training/educational needs- Learning experiences

	Health professionals’ engagements and satisfaction with the intervention	- Involvement & Satisfaction (both rated on a 0–10 scale)

Patient factors	Patient behaviour: patient’s response to consults	- Patient’s response to consults, advices- Factors that influence patient’s response to nurses’ care, e.g., financial issues

	Patient motivation: the targeted healthcare professional’s (perceived) ability to motivate patients to adhere	- Motivating patients to adhere

	Patient preferences: the targeted healthcare professional’s (perceived) ability to pay attention to patient preferences	- Paying attention to patient preferences

Professional interactions	Referral processes: processes for communication between the targeted healthcare professionals and targeted patients	- Nurse’s interaction with GPs- Nurse’s interaction with community pharmacists- Nurse’s interaction between GPs and community pharmacists

Incentives and resources	Financial incentives: the extent to which patients, individual health professionals and organisations have financial incentives or disincentives to adhere	- Financial issues that influenced adherence among patients, GPs and community pharmacists

	Information system: the extent to which the EHR facilitates or hinders adherence	- EHR

Capacity for organisational change	Mandate, authority and accountability for making necessary changes	- Mandate for treatment change in participating women.

	Regulations, rules, policies: the extent to which organisational regulations, rules or policies facilitate or hinder necessary changes.	- Regulations, rules and policies.

Social, political and legal factors	Payer or funder policies: the extent to which payer or funder policies may affect implementation of necessary changes	- Payer or funder policies facilitating or hindering implementation of necessary changes

	Legislation: the extent to which legislation may affect implementation of necessary changes	- Legislation affecting implementation of necessary changes

Factors	Concepts	Health professionals’ experiences, barriers and facilitators & possible improvements with regard to:

Gui	Feasibility of the recommended guideline and the protocol derived from the guidel	- Guideline- Protocol- EHR- Consults- Collaboration with other continence professionals: Informing the woman’s

deline related factors	ine	 GP after the consult by means of a letter, Advices for referrals, diagnostics and treatments

	Compatibility of the protocol: the extent to which the recommended protocol is practical	likewise

Individual health professional factors	Competences (=skills, attitude and knowledge) needed: the extent to which the targeted health professionals have competences they need	- Competences needed- Training/educational needs- Learning experiences

	Health professionals’ engagements and satisfaction with the intervention	- Involvement & Satisfaction (both rated on a 0–10 scale)

Patient factors	Patient behaviour: patient’s response to consults	- Patient’s response to consults, advices- Factors that influence patient’s response to nurses’ care, e.g., financial issues

	Patient motivation: the targeted healthcare professional’s (perceived) ability to motivate patients to adhere	- Motivating patients to adhere

	Patient preferences: the targeted healthcare professional’s (perceived) ability to pay attention to patient preferences	- Paying attention to patient preferences

Professional interactions	Referral processes: processes for communication between the targeted healthcare professionals and targeted patients	- Nurse’s interaction with GPs- Nurse’s interaction with community pharmacists- Nurse’s interaction between GPs and community pharmacists

Incentives and resources	Financial incentives: the extent to which patients, individual health professionals and organisations have financial incentives or disincentives to adhere	- Financial issues that influenced adherence among patients, GPs and community pharmacists

	Information system: the extent to which the EHR facilitates or hinders adherence	- EHR

Capacity for organisational change	Mandate, authority and accountability for making necessary changes	- Mandate for treatment change in participating women.

	Regulations, rules, policies: the extent to which organisational regulations, rules or policies facilitate or hinder necessary changes.	- Regulations, rules and policies.

Social, political and legal factors	Payer or funder policies: the extent to which payer or funder policies may affect implementation of necessary changes	- Payer or funder policies facilitating or hindering implementation of necessary changes

	Legislation: the extent to which legislation may affect implementation of necessary changes	- Legislation affecting implementation of necessary changes


	10-year breast cancer specific	5-year BDDM

Variant	P-value	HR	95% CI	P-value	HR	95% CI

-903GA	0.01521	1.90	1.13 to 3.20	0.00201	2.07	1.31 to 3.29


DT sensitivity, ψ	DT duration (days)	Total radiation (Gy)	TCP


 	Clonidine group 	Clonidine and Dextromethorphan group	P value

Number of patients 	30	30	—

Initial symptoms score 	2.7 ± 1.9	3.4 ± 2.6	0.17

Age 	29.3 ± 3.5	28.9 ± 4.3	0.56

Systolic blood pressure 	125.2 ± 13.6	125.4 ± 12.5	0.67

Diastolic blood pressure	75.4 ± 10.1	74.9 ± 10.1	0.98

	Clonidine group	Clonidine and Dextromethorphan group	P value

Number	3	30

 of patients	0		—

Initial symptoms score	2.7 ± 1.9	3.4 ± 2.6	0.17

Age	29.3 ± 3.5	28.9 ± 4.3	0.56

Systolic blood pressure	125.2 ± 13.6	125.4 ± 12.5	0.67

Diastolic blood pressure	75.4 ± 10.1	74.9 ± 10.1	0.98


	Active Synchronous	Passive Synchronous	Active Synchronous	Active Asynchronous

	Congruent	Congruent	Incongruent	Congruent

FMD group

Ownership statements vs. Ownership controls	Z = -3.757; p < 0.001	Z = -3.427; p = 0.001	Z = -2.379; p = 0.017	Z = -0.880; p = 0.379

Agency statements Vs. Agency controls	Z = -3.542; p < 0.001	Z = -1.700; p = 0.089	Z = -4.019; p < 0.001	Z = -0.916; p = 0.360

Ownership statements vs. Agency statements	Z = -2.534; p = 0.011	Z = -3.082; p = 0.002	Z = -3.827; p < 0.001	Z = -2.508; p = 0.012

HC group

Ownership statements vs. Ownership controls	Z = -3.666; p < 0.001	Z = -3.626; p < 0.001	Z = -3.163; p = 0.002	Z = -0.427; p = 0.669

Agency statements vs. Agency controls	Z = -3.925; p < 0.001	Z = -0.987; p = 0.324	Z = -3.927; p < 0.001	Z = -1.442; p = 0.149

Ownership statements vs. Agency statements	Z = -3.341; p = 0.001	Z = -2.834; p = 0.005	Z = -3.788; p < 0.001	Z = -1.661; p = 0.097

	Active Synchronous	Passive Synchronous

	Congruent	Congruent

FMD group

Ownership statements vs. Ownership controls	Z = -3.757; p < 0.001	Z = -3.427; p = 0.001

Agency statements Vs. Agency controls	Z = -3.542; p < 0.001	Z = -1.700; p = 0.089

Ownership statements vs. Agency statements	Z = -2.534; p = 0.011	Z = -3.082; p = 0.002

HC group

Ownership statements vs. Ownership controls	Z = -3.666; p < 0.001	Z = -3.626; p < 0.001

Agency statements vs. Agency controls	Z = -3.925; p < 0.001	Z = -0.987; p = 0.324

Ownership statements vs. Agency statements	Z = -3.341; p = 0.001	Z = -2.834; p = 0.005


Characteristic	Frequency	Percent	M (SD)	Range

Age			51.50 (14.56)	18–89

Duration of RD symptoms in years			18.84 (16.49)	0–75

Years since RD diagnosis			9.76 (11.46)	0–70

Number of RDs perparticipant

 1	1058	87%

 2	130	11%

 3	22	2%

 4	4	<1%

 5	4	<1%

Gender

 Female	935	77%

 Male	279	23%

 Other	4	<1%

Income

 under $10,000	58	5%

 $10,000–20,000	95	8%

 $20,001–30,000	118	10%

 $30,001–45,000	127	11%

 $45,001–60,000	161	14%

 $60,001–75,000	128	11%

 $75,001–90,000	107	9%

 $90,001 and above	376	32%

Race/ethnicity

 American Indian orAlaska native	11	1%

 Asian	23	2%

 Black or African American	13	1%

 Hispanic or Latino/a	31	3%

 Native Hawaiian orPacific Islander	2	6%

 White	1149	94%

 Other	31	3%

Characteristic	Frequency

Age

Duration of RD symptoms in years

Years since RD diagnosis

Number of RDs perparticipant

1	1058

2	130

3	22

4	4

5	4

Gender

Female	935

Male	279

Other	4

Income

under $10,000	58

$10,000–20,000	95

$20,001–30,000	118

$30,001–45,000	127

$45,001–60,000	161

$60,001–75,000	128

$75,001–90,000	107

$90,001 and above	376

Race/ethnicity

American Indian orAlaska native	11

Asian	23

Black or African American	13

Hispanic or Latino/a	31

Native Hawaiian orPacific Islander	2

White	1149

Other	31


 	Tumbi hospital (%)	Dodoma hospital (%)	All (%)

Occupational injury

Needle stick (used needle)	64 (37.4)*	41 (17.8)	105 (26.2)

Blood stained sharp objects	64 (37.4)*	37 (16.1)	101 (25.2)

Blood or body fluid splash	81 (47.4)*	73 (31.7)	154 (38.4)

Blood or body fluid contact with ulcerated or abraded skin	63 (36.8)*	38 (16.5)	101 (25.2)

Human bite	45 (26.3)*	21 (9.1)	66 (16.5)

At least one occupational injury	98 (57.3)*	94 (40.9)	192 (47.9)

Managing occupational exposure

Good practice	118 (69.0)	158 (68.7)	276 (68.8)


Year	2010	2010

Group	BFM	Japanese Childhood AML Cooperative Study

Induction Therapy	ATRA+IDA+VP/CA+VP+DNR	ATRA+IDA+CA

No. of Pts	81	58

Consolidation Therapy	CA+IDA+HD-CA+VP16	HD-CA+MTZ+ATRA+PIRARUBI CIN+ACLARUBICIN

EFS (%)	73 (5 years)	91 (7 years)

OS (%)	89 (5 years)	93 (7 years)

Year	2010

Group	BFM

Induction Therapy	ATRA+IDA+VP/CA+VP+DNR

No. of Pts	81

Consolidation Therapy	CA+IDA+HD-CA+VP16

EFS (%)	73 (5 years)

OS (%)	89 (5 years)

2010

Japanese Childhood AML Cooperative Study

ATRA+IDA+CA

58

HD-CA+MTZ+ATRA+PIRARUBI CIN+ACLARUBICIN

91 (7 years)

93 (7 years)


Variables	Group C (n = 35)	Group T (n = 35)	P value

Group 1	19	17

Group 2	16	18

Intraoperative ephedrine use			1.000

yes(n)	4	5

No(n)	31	30

Intraoperative antihypertensives			0.002

yes(n)	24	10*

No(n)	11	25


Characteristic	mean ± SD, or N(%)

Gender

Male	85 (38.3)

Female	137(61.7)

Marital status

Married	205 (92.3)

Not married	17 (7.7)

Mean age (years)	64.5 ± 6.4

Age categories

<60	48 (21.6)

60-69	119 (53.6)

≥70	55 (24.8)

Education

Illiteracy or elementary school	21 (9.5)

Junior high school	85 (38.3)

Senior high school	64 (28.8)

Technical school or college	52 (23.4)

Family per capita month income (RMB)

<2000	102 (45.9)

≥2000	120 (54.1)

Family history of diabetes

Yes	86 (38.7)

No	136 (61.3)

Clinical symptoms

Yes	96 (43.2)

No	126 (56.8)

Complications

Yes	155 (69.8)

No	67 (30.2)

Duration of diabetes (years)

<4	64 (28.8)

5-9	72 (32.4)

10-14	56 (25.2)

≥15	30 (13.5)

Mean BMI (kg/m2)	24.9 ± 3.4

BMI categories*

<24	91 (41.0)

≥24	131 (59.0)

Characteristic	mean ± SD, or N(%)

Gender

Male	85 (38.3)

Female	137(61.7)

Marital status

Married	205 (92.3)

Not married	17 (7.7)

Mean age (years)	64.5 ± 6.4

Age categories

<60	48 (21.6)

60-69	119 (53.6)

≥70	55 (24.8)

Education

Illiteracy or elementary school	21 (9.5)

Junior high school	85 (38.3)

Senior high school	64 (28.8)

Technical school or college	52 (23.4)

Family per capita month income (RMB)

<2000	102 (45.9)

≥2000	120 (54.1)

Family history of diabetes

Yes	86 (38.7)

No	136 (61.3)

Clinical symptoms

Yes	96 (43.2)

No	126 (56.8)

Complications

Yes	155 (69.8)

No	67 (30.2)

Duration of diabetes (years)

<4	64 (28.8)

5-9	72 (32.4)

10-14	56 (25.2)

≥15	30 (13.5)

Mean BMI (kg/	24.9

Characteristic	mean ± SD, or N(%)

m2)	± 3.4

BMI categories*

<24	91 (41.0)

≥24	131 (59.0)


Item	X1 (h)	X2 (°C)	X3 (Ac:Al) a	X4 (%)	Predicted yield (%)	Experimental yield (%)


General recommendations	Rehabilitation should be undertaken by individuals with relevant skills and knowledge communication between teams and professionals over the rehabilitation pathway should occur

Pathway-specific recommendations

During critical care stay	Assess risk of post-ICU disability

Commence goal-oriented rehabilitation early

Involve families and carers

Provide illness-related information to patient and family

Optimise provision of nutrition

At ICU discharge	Screen patient for physical and psychological issues

Plan individualised rehabilitation programme with defined goals

Provide information to patients and families about rehabilitation pathway, likely morbidity, ICU stay, and transition to general ward environment

During ward based care	Repeat screening for physical and psychological issues

Offer individualised rehabilitation programme with defined goals, provided by a multidisciplinary team

Regularly update rehabilitation programme and goals, making specialist referral where appropriate

Offer structured self-directed and supported rehabilitation manual for at least 6 weeks to appropriate patients

Prior to hospital discharge	Perform a functional assessment including physical and psychological elements, evaluating the impact on patient activities of daily living and participation

Ensure support for outstanding issues are arranged, including ongoing rehabilitation by community services

Provide patient and family with relevant information, including information about their ICU stay

At 2–3 months post-ICU discharge	Review patient as outpatient and perform functional assessment

Refer for ongoing rehabilitation and/or specialist support according to individual need

Adapted from [36]

General recommendations

Pathway-specific recommendations

During critical care stay

At ICU discharge

During ward based care

Prior to hospital discharge

At 2–3 months post-ICU discharge

Adapted from [36]

Rehabilitation should be undertaken by individuals with relevant skills and knowledge communication between teams and professionals over the rehabilitation pathway should occur

Assess risk of post-ICU disability

Commence goal-oriented rehabilitation early

Involve families and carers

Provide illness-related information to patient and family

Optimise provision of nutrition

Screen patient for physical and psychological issues

Plan individualised rehabilitation programme with defined goals

Provide information to patients and families about rehabilitation pathway, likely morbidity, ICU stay, and transition to general ward environment

Repeat screening for physical and psychological issues

Offer individualised rehabilitation programme with defined goals, provided by a multidisciplinary team

Regularly update rehabilitation programme and goals, making specialist referral where appropriate

Offer structured self-directed and supported rehabilitation manual for at least 6 weeks to appropriate patients

Perform a functional assessment including physical and psychological elements, evaluating the impact on patient activities of daily living and participation

Ensure support for outstanding issues are arranged, including ongoing rehabilitation by community services

Provide patient and family with relevant information, including information about their ICU stay

Review patient as outpatient and perform functional assessment

Refer for ongoing rehabilitation and/or specialist support according to individual need

Adapted from [36]


SNP-candidates	Morph	Uni	Rep

Total		96231	74341

Filter coverage		66569	57009

Diff. Bwn. samples		21417	22252

Diff. Bwn. morphs		11385	12953

Delta > 0.5	AC	396	285

Delta > 0.5	SB	526	353

Delta > 0.75	AC	95	68

Delta > 0.75	SB	155	95

Delta > 0.95	AC	17	13

Delta > 0.95	SB	29	4


Variables	Frequency (percentage)

Gender (females)	212 (58.1)

Age at diagnosis (years):

 	≤ 5	24 (6.6)

 	6–10	170 (46.6)

 	11-15	171 (46.8)

Residence (urban or semi-urban):	178 (48.8)

Mitral valve disease	359 (98.4)

Pure mitral stenosis (all grades)	35 (10.0)

Mitral stenosis with regurgitation (all grades)	91 (24.9)

Mitral regurgitation, no stenosis (all grades)	233 (63.8)

Multi-valvular involvement (mitral valve disease included):

Aortic valve disease (regurgitation and/or stenosis)	257 (70.4)

Tricuspid valve disease (regurgitation and/or stenosis)	299 (81.9)

Mean transmitral diastolic pressure gradient (n = 108):

 	<10 mmHg	4 (3.5)

 	10 – 20 mmHg	40 (35.7)

 	21 – 30 mmHg	61 (54.5)

 	>30 mmHg	3 (2.7)

Mitral valve score for severe mitral stenosis (n = 19)

 	≤8	2 (10.5)

 	>8	17 (89.5)

Functional class (New York Heart Association):

 	I	10 (2.7)

 	II	276 (75.6)

 	III	27 (7.4)

 	IV	52 (14.2)

On secondary prophylaxis against recurrence of rheumatic fever (at the time of referral)	272 (74.5)


Variable	Odds ratio	95% confidence interval	Coefficient	S.E.	Significance

Predisposing

Race/ethnicity (ref. = non-Hispanic White)

Black	1.738	1.371	2.203	0.552	0.120	***

Hispanic/Latina	1.799	1.126	2.875	0.587	0.239	**

Other race	0.726	0.444	1.187	−0.319	0.250

Age	1.000	0.992	1.009	0.001	0.004

Educational attainment (ref. = no high school diploma)

Hig	1	0.781	1		0.1


Method: 95% LSD

Pass	Count	LS Mean	Homogeneous Groups


Transgene	Description	Efficacy	Promoter	Assay	Publication

R2	SIV rev + env shRNA	68%–80% inhibition of viral replication	U6	SIV challenge, CEMx174 cell line	Parket al. 2005 [77]

L2R	HIV LTR + rev miRNA cassette	>98% inhibition of viral replication	CMV	HIV challenge, U87.CD4.CXCR4 cell line	Parket al. 2009 [78]

TAR + L2R	Tat inducible HIV LTR + rev miRNA cassette + TAR	>98% inhibition of viral replication	Tat inducible LTR-Hsp fusion

TAR + R	Tat inducible rev miRNA cassette + TAR	>98% inhibition of viral replication	Tat-inducible LTR-Hsp fusion

TAR	TAR	>98% inhibition of viral replication	LTR

Sh1	anti tat/rev shRNA	4 log reduction of viral replication	U6	HIV challenge, CD34-derived macrophages	Tayloret al. 2008 [79]

C46	membrane associated fusion inhibitor	4 log reduction of viral replication	MSCV

Sh1 + C46 + RevM10	tat/rev shRNA + membrane-associated fusion inhibitor + dominant negative Rev	significantly increased relative to C46 alone	U6, MSCV, PGK	HIV challenge of protected and unprotected cells in CEMx174 cell line

C46	membrane associated fusion inhibitor	5.2-fold increase in cell survival +3.1-fold decrease in HIV p24/cell	MSCV

4 log reduction of viral replication	SFFV	SHIV challenge, CEM.NKR-CCR5 lymphocytes	Kiemet al. 2010 [27]

15–20 fold reduction of viral replication	SFFV	SHIV or HIV single viral cycle challenge, MAGI-CCR5 cell line

SI + C46	tat/rev shRNA + membrane associated fusion inhibitor	5 fold reduction of viral replication	U6, SFFV

SII + SI + R5 + C46	two tat/rev shRNAs + CCR5 shRNA + membrane associated fusion inhibitor	23 fold reduction of viral replication	H1, SFFV

4 log reduction of viral replication	SHIV challenge, CEM.NKR-CCR5 lymphocytes

SI + C46	tat/rev shRNA + C46	4 log reduction of viral replication	U6, SFFV

SII + SI + R5	two tat/rev shRNAs + CCR5 shRNA	180 fold reduction of viral replication	H1

Transgene	Description	Efficacy	Promoter	Assay	Publication

Sh1 + C46 + RevM10	tat/rev shRNA + membrane-associated fusion inhibitor + dominant negative Rev	significantly increased relative to C46 alone	U6, MSCV, PGK	HIV challenge of protected and unprotected cells in CEMx174 cell line	Tayloret al. 2008 [79]

C46	membrane associated fusion inhibitor	5.2-fold increase in cell survival +3.1-fold decrease in HIV p24/cell	MSCV

4 log reduction of viral replication	SFFV	SHIV challenge, CEM.NKR-CCR5 lymphocytes	Kiemet al. 2010 [27]

15–20 fold reduction of viral replication	SFFV	SHIV or HIV single viral cycle challenge, MAGI-CCR5 cell line

SI + C46	tat/rev shRNA + membrane associated fusion inhibitor	5 fold reduction of viral replication	U6, SFFV

SII + SI + R5 + C46	two tat/rev shRNAs + CCR5 shRNA + membrane associated fusion inhibitor	23 fold reduction of viral replication	H1, SFFV

4 log reduction of viral replication	SHIV challenge, CEM.NKR-CCR5 lymphocytes

SI + C46	tat/rev shRNA + C46	4 log reduction of viral replication	U6, SFFV

SII + SI + R5	two tat/rev shRNAs + CCR5 shRNA	180 fold reduction of viral replication	H1


Lesion	Age	Site	Cytomorphology	IHQ

Ganglioneuroma	80% < 10 years	Retroperitoneum, posterior mediastinum, pelvis, head and neck	Mature ganglion cells, myxoid stroma, schwann cells, neurites	NSE, Syp, PS-100 (+)CK, Actin (-)

Ganglioneuroblastoma	90% < 5 years	Retroperitoneum, posterior mediastinum	Neuroblasts, rosettes, neuropil, mature ganglion cells, myxoid stroma, schwann cells, neurites	NSE, Syp, PS-100 (+)CK, Actin (-)

Neuroblastoma	90% < 5 years	Retroperitoneum, posterior mediastinum	Neuroblasts, rosettes, neuropil, necrosis	NSE, Syp, PS-100, NbP (+)CK, Actin (-)

Nerve Sheath Tumors	30–50 years	Posterior mediastinum, retroperitoneum, limbs	Cohesive aggregates of spindle cells, myxoid background	NSE, PS-100 (+)CK, Actin (-)

Proliferative fasciitis, Proliferative myositis	All ages	Limbs, head and neck, chest wall	Spindle cells, plump cells ganglion cell-like cells, lack of myxoid background	Vimentin, Actin, PS-100, SMA (+)Syp, CK, NSE (-)

Lesion	Age	Site	Cytomorphology	IHQ

Ganglioneuroma	80% < 10 years	Retroperitoneum, posterior mediastinum, pelvis, head and neck	Mature ganglion cells, myxoid stroma, schwann cells, neurites	NSE, Syp, PS-100 (+)CK, Actin (-)

Ganglioneuroblastoma	90% < 5 years	Retroperitoneum, posterior mediastinum	Neuroblasts, rosettes, neuropil, mature ganglion cells, myxoid stroma, schwann cells, neurites	NSE, Syp, PS-100 (+)CK, Actin (-)

Neuroblastoma	90% < 5 years	Retroperitoneum, posterior mediastinum	Neuroblasts, rosettes, neuropil, necrosis	NSE, Syp, PS-100, NbP (+)CK, Actin (-)

Nerve Sheath Tumors	30–50 years	Posterior mediastinum, retroperitoneum, limbs	Cohesive aggregates of spindle cells, myxoid background	NSE, PS-100 (+)CK, Actin (-)

Proliferative fasciitis, Prolifer	All 	Lim	Spindle cells	Vimentin, Act

Lesion	Age	Site	Cytomorphology	IHQ

ative myositis	ages	bs, head and neck, chest wall	, plump cells ganglion cell-like cells, lack of myxoid background	in, PS-100, SMA (+)Syp, CK, NSE (-)


Professional category	Grade	Experience/ service	Annual salary prior to OSD	Annual salary as at 1 July 2009	Total annual salary package as at 1 July 2009*	% Increase Year 1	% Accumulative increase Year 2

Medical intern			R117 501 ($13873)^	R228 828 ($27016)	R314 023 ($37075)	31 % - 53%

Medical officer (Community service)			R174 243 ($20572)	R286 086 ($33776)	R392 599 ($46352)	9.8 % - 18.9%	6.1%

Medical officer	Grade 1	0 – 4 years	R174 243 ($20572)	R332 016 ($39199)	R365 217 ($43119)	9 % - 25%	12%

	Grade 2	5 – 9 years	R247 512 ($29222)	R385 314 ($45492)	R423 846 ($50041)	26 % - 44%	14%

Professional category	Grade	Experience/ service	Annual salary prior to OSD	Annual salary as at 1 July 2009	Total annual salary package as at 1 July 2009*	% Increase Year 1	% Accumulative increase Year 2

	Grade 3	> 10 years	R391 026 ($46166)	R447 174 ($52795)	R491 892 ($58075)	46 % - 68%	20%

Medical specialist	Grade 1	0 – 4 years			R491 892 ($58075)	1.8 % - 18%	13%

	Grade 2	5 – 9 years			R554 109 ($65420)	14.7 % - 32.9%	20%

	Grade 3	> 10 years			R624 198 ($73695)	29.2 % - 49.8%	26%

Principal specialist			R769 271 - R962 174 ($90823-113598)		R932 399 ($110083)	4.6 % - 25.1%

Chief specialist			R932 399 ($110083)		R1.2 million ($141677)	7.9 % - 29%


Sliding window (SW)	Most significant result

HCV Genotype

 	 	1	2	1	2

SNPs/SW	No. of SW	SW	SW	Pvalue	Pvalue

1	4	-	-	-	-

2	3	S1.S2	S3.S4	0.0208*	0.0546

3	2	S2.S4	S2.S4	0.0540	0.1099

4	1	S1.S4	S1.S4	0.0397*	0.1585


	AP group	EP group

Number of patients	149	150

Sex


MicroRNA	No. of brain-expressed target genes	No. of brain-expressed target genes, P<0.05	P enrichment	No. of significant targets (corr)	No. of significant pathways

miR-499-5p	286	59	0.7172	4	12

miR-708-5p	174	37	0.9265	2	1

miR-1908-5p	56	17	0.1422	1	5

MicroRNA	No. of brain-expressed target genes	No. of brain-expressed target genes, P<0.05	P enrichment	No. of significant targets (corr)	No. of significant pathways

miR-1908-5p	56	17	0.1422	1	5


	FEV1 loss < 15% (n = 28)	FEV1 loss ≥15% (n = 7)	p-value

s*	1 (17)	(17)	.42

Total exposure time (months)	46 (91)	62 (169)	0.32

Symptomatic exposure time (months)	11 (19)	19 (49)	0.40


Antigen	Labeled cells	Clone	Conjugate	Sourcea

CD45	Pan-leukocyte	YKIX716.13	PE	AbD Serotec

CD18	Pan-leukocyte	CA1.4E9	AF647	AbD Serotec

CD3	T cells	CA17.2A12	FITC	AbD Serotec

CD5	T cells	YKIX322.2	PE	AbD Serotec

CD4	T helper/regulatory cells, neutrophils, activated monocytes	YKIX302.9	FITC	AbD Serotec

CD8α	Cytotoxic T cell	YCATE55.9	PE	AbD Serotec

TCRαβ	T cells	CA15.8G7	None	UC-Davis

CD21	B cells	B-ly4	PE	BD-Biosciences

CD22	B cells	RFB4	PE	Abcam

CD14	Monocytes	Tük4	PE	Dako

CD34	Stem cell	1H6	PE	BD-Biosciences

MHCII	Lymphocytes, monocytes	YKIX334.2	FITC	AbD Serotec

CD11b	Neutrophils, monocytes	CA16.3E10	None	AbD Serotec

CD11c	Monocytes, neutrophils,	CA11.6A1	None	AbD Serotec

CD11d	T subset, some monocytes	CA11.8H2	None	AbD Serotec

CD1c	T subset, B subset, monocytes	CA13.9H11	None	UC-Davis

Anti-pmn	Neutrophil	CAD048A	None	VMRD

CD90 (Thy-1)	Lymphocytes, monocytes, stem cells, eosinophils	CA1.4G8	None	UC-Davis

CD61	Platelets	SZ21	PE	Beckman-Coulter

Antigen

CD45

CD18

CD3

CD5

CD4

CD8α

TCRαβ

CD21

CD22

CD14

CD34

MHCII

CD11b

CD11c

CD11d

CD1c

Anti-pmn

CD90 (Thy-1)

CD61

Labeled cells	Clone	Conjugate	Sourcea

Pan-leukocyte	YKIX716.13	PE	AbD Serotec

Pan-leukocyte	CA1.4E9	AF647	AbD Serotec

T cells	CA17.2A12	FITC	AbD Serotec

T cells	YKIX322.2	PE	AbD Serotec

T helper/regulatory cells, neutrophils, activated monocytes	YKIX302.9	FITC	AbD Serotec

Cytotoxic T cell	YCATE55.9	PE	AbD Serotec

T cells	CA15.8G7	None	UC-Davis

B cells	B-ly4	PE	BD-Biosciences

B cells	RFB4	PE	Abcam

Monocytes	Tük4	PE	Dako

Stem cell	1H6	PE	BD-Biosciences

Lymphocytes, monocytes	YKIX334.2	FITC	AbD Serotec

Neutrophils, monocytes	CA16.3E10	None	AbD Serotec

Monocytes, neutrophils,	CA11.6A1	None	AbD Serotec

T subset, some monocytes	CA11.8H2	None	AbD Serotec

T subset, B subset, monocytes	CA13.9H11	None	UC-Davis

Neutrophil	CAD048A	None	VMRD

Lymphocytes, monocytes, stem cells, eosinophils	CA1.4G8	None	UC-Davis

Platelets	SZ21	PE	Beckman-Coulter


		Results of conventional RT-PCR	Total

		Positive	Negative

Results of NanoSign® Influenza A/B antigen kit	Positive	158	23	181

	Negative	41	801	842

Total	199	824	1,023


Independent variables	Unadjusted Rate Ratio (95 % CI)a	P value	Adjusted Rate Ratio (95 % CI)b	P value

Age at each pre-recruitment year (per year)	1.0 (1.0. 1.0)	0.048	1.0 (1.0, 1.0)	0.012


Patients with:

2 positive Criteria		Crit1+	Crit2+	Crit3+	Crit4+

	Crit2+	11

	Crit3+	75	36

	Crit4+	10	7	19

	Crit5+	9	2	4	4

3 positive Criteria		Crit12+	Crit13+	Crit14+	Crit23+	Crit24+

	Crit3+	109

	Crit4+	4	39		10

	Crit5+	9	78	5	5	8

4 positive Criteria	Crit1234+	Crit1235+	Crit1245+	Crit1345+	Crit2345+

	22	37	9	63	0

5 positive Criteria	Crit12345+

	35

Patients with:

	Crit5+	9	2	4	4

3 positive Criteria		Crit12+	Crit13+	Crit14+	Crit23+	Crit24+

	Crit3+	109

	Crit4+	4	39		10

	Crit5+	9	78	5	5	8

4 positive Criteria	Crit1234+	Crit1235+	Crit1245+	Crit1345+	Crit2345+

	22	37	9	63	0

5 positive Criteria	Crit12345+

	35


No.	Group	Treatment	Radiationa	Microgravity

1	Spaceflight	Spaceflight static slot	1.92 mGy	μg

2	Spaceflight control	Spaceflight 1g-centrifuge slot	2.27 mGy	1g

3	Ground control	Ground static slot	–	1g


Characteristics	Variables	AMA (%)	STMA (%)

Gender	Male	27	26

Female	23	24

Marital status	Single (never married)	6.1	2.7

Married	32.7	40.1

Cohabitation	2	2

Separated	1.4	2.7

Divorced	5.4	1.4

Widowed	3.4	0

Level of education	No education	15.4	12.8

Primary	16.8	15.4

Secondary	16.1	17.4

Tertiary	2	4

Employment	No	36.7	33.3

Yes	14.3	15.7

Age group	40–44	2	3.3

45–49	11	7.3

50–54	12	8

55–59	8.7	10.7

60–64	6	6.7

65–69	4	6

70+	6	8

Number of years living in the city (year group)	35–39	13.3	10.7

40–44	8	10

45–49	10.7	9.3

50–54	7.3	6

55–59	4.7	6

60–64	2	2.7

65–69	2	1.3

70+	2	4

 	N = 150	 75	75


Pollutants	No. of other sites	Median correlation (range)

Fine particles and components

24-hr avg PM2.5	12b	0.88 (0.46–0.95)

24-hr avg PM2.5	3c	0.88 (0.76–0.95)

Major ions

24-hr avg SO42–	3	0.90 (0.76–0.94)

24-hr avg NO3–	3	0.88 (0.75–0.90)

Carbon

24-hr avg OC	3	0.43 (0.38–0.69)

24-hr avg EC	3	0.47 (0.37–0.52)

Metals and metalloids

24-hr avg Si	3	0.96 (0.68–0.96)

24-hr avg K	3	0.71 (0.60–0.74)

24-hr avg Ca	3	0.35 (0.30–0.37)

24-hr avg Fe	3	0.54 (0.39–0.74)

24-hr avg Cu	3	0.03 (–0.09–0.05)

24-hr avg Zn	3	0.03 (–0.02–0.11)

24-hr avg Pb	3	0.08 (0.04–0.22)

Criteria gases

8-hr max O3	13d	0.85 (0.72–0.94)

1-hr max CO	3	0.62 (0.17–0.71)

1-hr max NO2	8	0.64 (0.27–0.70)

1-hr max SO2	10	–0.03 (–0.10–0.12)

Abbreviations: avg, average; max, maximum. aThese are partial correlations, computed as the correlations between residuals from linear models for each of the pollutants that included all of the covariates in our epidemiologic models; all correlations exclude data from 4 July 2001, 4 July 2002, and 5 July 2002. bIncludes data from all sites at which PM2.5 was measured. cIncludes data from a subset of PM2.5 sites at which PM2.5 components were also measured (every 3 or 6 days). dOnly two sites other than Tudor Ave. provided year-round O3 data; restricting the analysis to these sites produced similar results: median, 0.84 (range, 0.82–0.87).

Pollutants	No. of other sites

Fine particles and components

24-hr avg PM2.5	12b

24-hr avg PM2.5	3c

Major ions

24-hr avg SO42–	3

24-hr avg NO3–	3

Carbon

24-hr avg OC	3

24-hr avg EC	3

Metals and metalloids

24-hr avg Si	3

24-hr avg K	3

24-hr avg Ca	3

24-hr avg Fe	3

24-hr avg Cu	3

24-hr avg Zn	3

24-hr avg Pb	3

Criteria gases

8-hr max O3	13d

1-hr max CO	3

1-hr max NO2	8

1-hr max SO2	10

Abbreviations: avg, average; max, maximum. aThese are partial correlations, computed as the correlations between residuals from linear models for each of the pollutants that included all of the covariates in our epidemiologic models; all correlations exclude data from 4 July 2001, 4 July 2002, and 5 July 2002. bIncludes data from all sites at which PM2.5 was measured. cIncludes data from a subset of PM2.5 sites at which PM2.5 components were also measured (every 3 or 6 days). dOnly two sites other than Tudor Ave. provided year-round O3 data; restricting the analysis to these sites produced similar results: median, 0.84 (range, 0.82–0.87).

Median correlation (range)

0.88 (0.46–0.95)

0.88 (0.76–0.95)

0.90 (0.76–0.94)

0.88 (0.75–0.90)

0.43 (0.38–0.69)

0.47 (0.37–0.52)

0.96 (0.68–0.96)

0.71 (0.60–0.74)

0.35 (0.30–0.37)

0.54 (0.39–0.74)

0.03 (–0.09–0.05)

0.03 (–0.02–0.11)

0.08 (0.04–0.22)

0.85 (0.72–0.94)

0.62 (0.17–0.71)

0.64 (0.27–0.70)

–0.03 (–0.10–0.12)

Abbreviations: avg, average; max, maximum. aThese are partial correlations, computed as the correlations between residuals from linear models for each of the pollutants that included all of the covariates in our epidemiologic models; all correlations exclude data from 4 July 2001, 4 July 2002, and 5 July 2002. bIncludes data from all sites at which PM2.5 was measured. cIncludes data from a subset of PM2.5 sites at which PM2.5 components were also measured (every 3 or 6 days). dOnly two sites other than Tudor Ave. provided year-round O3 data; restricting the analysis to these sites produced similar results: median, 0.84 (range, 0.82–0.87).


	Tertiary hospitals (n = 50) Mean (SD) score	General hospitals (n = 109) Mean (SD) score

Reduction of rate of intubation and ventilation	4.5 (1.0)	4.8 (0.7)

Reduction in need for inter-hospital transfer	4.0 (1.2)	4.7 (0.7)

Reduction in length of stay	3.9 (1.0)	4.2 (0.8)

Reduction in complication rate	3.9 (1.2)	4.3 (0.9)

Improved patient tolerance	3.9 (1.1)	4.2 (0.9)

Reduced need for sedation	3.6 (1.2)	3.5 (1.2)

Parent/Carer Satisfaction	4.0 (0.9)	3.9 (1.1)

	 hospitals (n = 50) Mean (SD) score	 Mean (SD) score

Reduction of rate of intubation and ventilation	4.5 (1.0)	4.8 (0.7)

Reduction in need for inter-hospital transfer	4.0 (1.2)	4.7 (0.7)

Reduction in length of stay	3.9 (1.0)	4.2 (0.8)

Reduction in complication rate	3.9 (1.2)	4.3 (0.9)

Improved patient tolerance	3.9 (1.1)	4.2 (0.9)

Reduced need for sedation	3.6 (1.2)	3.5 (1.2)

Parent/Carer Satisfaction	4.0 (0.9)	3.9 (1.1)


Measurement year	2008	2010	2013

Participation

All measured children (n, % of eligible)	1142 (86)	1448 (85)	1868 (91)

Girls/boys (% of eligible)	85/86	84/85	91/90

Completed FQ (n, % of measured)	833 (73)	1085 (75)	1134 (61)

Girls/boys (% of measured)	76/70	76/74	61/61

Distribution of children according to individual socioeconomic characteristics from FQ

Maternal education % low/high	54/46	55/45	44/56

Maternal employment	79/21	82/18	85/15

% employed/not employed1


Importance of the Water Supply Issue to the Household	Percentage

Absolutely not important	10

Not important	10

Between important and not important	8

Important	38

Very important	34

Importance of the Water Supply Issue to the Household	Percentage

Absolutely not important	10

Not important	10

Between important and not important	8

I	38

Importance of the Water Supply Issue to the Household	Percentage

mportant

Very important	34


	Type 1 diabetes n = 199	All controls n = 178	p value

Sex (male:female)	98:101	84:94	0.69

Age (years)	14.4 ± 1.6	14.4 ± 2.1	0.80

Height (cm)	163 ± 10	162 ± 11	0.25

Weight (kg)	60.7 ± 14.3	54.7 ± 13.8	<0.0001

BSA (m2)	1.65 ± 0.22	1.57 ± 0.23	0.0006

Insulin administration (%)

 Pump	60.8	–

 Multiple injections	30.2	–

Smoking status n (%)

 Never smoked	181 (92.8)	63 (100)

 Smoked few puffs to a whole cigarette in my life	9 (4.6)	0

 Only 2 to 3 cigarettes in my life	1 (0.5)	0

 More than 3, but fewer than 100 cigarettes in my life	1 (0.5)	0

 >100 cigarettes in my life, none in the past month	1 (0.5)	0

 >100 cigarettes in my life, some in the last month but not every day	1 (0.5)	0

 >100 cigarettes in my life, at least 1 cigarette every day during the last month	2 [1]	0

BMI (kg/m2)	22.6 ± 4.3	20.6 ± 3.7	<0.0001

SBP (mmHg)	113 ± 10	110 ± 9	0.0005

SBP z-score for height	0.2 ± 0.9	−0.1 ± 0.9	0.0011

DBP (mmHg)	62 ± 7	58 ± 7	<0.0001

DBP z-score for height	−0.3 ± 0.6	−0.6 ± 0.7	<0.0001

MBP (mmHg)	77 ± 7	75 ± 7	0.0053

PP (mmHg)	51 ± 9	52 ± 8	0.48

HR (bpm)	66 ± 9	68 ± 12	0.036

Diabetes duration (years)	7.2 ± 3.1	–	−

Glucose (mmol/l)	9.7 ± 4.4	4.7 ± 0.7	<0.0001

HbA1c (%)	0.085 ± 0.012	0.054 ± 0.002	<0.0001

HbA1c mmol/mol	84.9 ± 12.4	53.8 ± 2.4	<0.0001

Cholesterol (mmol/L)	4.3 ± 0.88	4.24 ± 0.83	0.5158

HDL cholesterol (mmol/L)	1.6 ± 0.36	1.46 ± 0.28	0.0004

LDL cholesterol (mmol/L)	2.3 ± 0.71	2.36 ± 0.74	0.6109

Triglycerides (mmol/L)	0.84 ± 0.37	0.93 ± 0.40	0.0945

Creatinine (mmol/L)	54 ± 9	56 ± 11	0.1149

eGFR (mL/min/1.73 m2)	113 ± 17	108 ± 17	0.0405

	Type 1 diabetes n = 199	All controls n = 178	p value

ump	.8	–

Multiple injections	30.2	–

Smoking status n (%)

Never smoked	181 (92.8)	63 (100)

Smoked few puffs to a whole cigarette in my life	9 (4.6)	0

Only 2 to 3 cigarettes in my life	1 (0.5)	0

More than 3, but fewer than 100 cigarettes in my life	1 (0.5)	0

>100 cigarettes in my life, none in the past month	1 (0.5)	0

>100 cigarettes in my life, some in the last month but not every day	1 (0.5)	0

>100 cigarettes in my life, at least 1 cigarette every day during the last month	2 [1]	0

BMI (kg/m2)	22.6 ± 4.3	20.6 ± 3.7	<0.0001

SBP (mmHg)	113 ± 10	110 ± 9	0.0005

SBP z-score for height	0.2 ± 0.9	−0.1 ± 0.9	0.0011

DBP (mmHg)	62 ± 7	58 ± 7	<0.0001

DBP z-score for height	−0.3 ± 0.6	−0.6 ± 0.7	<0.0001

MBP (mmHg)	77 ± 7	75 ± 7	0.0053

PP (mmHg)	51 ± 9	52 ± 8	0.48

HR (bpm)	66 ± 9	68 ± 12	0.036

Diabetes duration (years)	7.2 ± 3.1	–	−

Glucose (mmol/l)	9.7 ± 4.4	4.7 ± 0.7	<0.0001

HbA1c (%)	0.085 ± 0.012	0.054 ± 0.002	<0.0001

HbA1c mmol/mol	84.9 ± 12.4	53.8 ± 2.4	<0.0001

Cholesterol (mmol/L)	4.3 ± 0.88	4.24 ± 0.83	0.5158

HDL cholesterol (mmol/L)	1.6 ± 0.36	1.46 ± 0.28	0.0004

LDL cholesterol (mmol/L)	2.3 ± 0.71	2.36 ± 0.74	0.6109

Triglycerides (mmol/L)	0.84 ± 0.37	0.93 ± 0.40	0.0945

Creatinine (mmol/L)	54 ± 9	56 ± 11	0.1149

eGFR (mL/min/1.73 m2)	113 ± 17	108 ± 17	0.0405


Healthcare professional	Gender	Description of Role

Respiratory Physician	Female	Assessment of COPD and comorbidities, preparation and review of COPD treatment plans

Registered Clinic Nurse	Female	Support assessments, administer aspects of treatment plan (eg smoking cessation counselling, instruction in inhaler technique, case coordination

Research Assistant	Female	Case coordination, data entry and management

General Practitioner	Male	Prepare health care plan, receive and integrate test results in between study visits, provide referrals to specialists, allied health and Respiratory HEAL


Specialty:

Radiation oncology vs. Urology	1.26	1.15, 1.38	<0.0001


Group	≤35 years old	36-38 years old	39-40 years old	>40 years old

Variable	RC	p	RC	p	RC	p	RC	p

Laboratory outcomes

Fertilization rate	-0.001	NS	0.000	NS	0.001	NS	-0.002	NS

High quality D3 embryos	-0.001	NS	0.000	NS	0.000	NS	0.000	NS

High quality Embryo rate	-0.005	<0.01	-0.006	0.025	0.002	NS	-0.002	NS

Blastocyst formation rate	-0.005	<0.01	-0.007	0.042	0.004	NS	-0.004	NS

Transferred embryos	0.000	<0.01	0.000	NS	0.000	NS	0.000	NS

Endometrium	0.000	NS	0.000	NS	0.001	NS	0.000	NS


 	All N = 15	18 years or younger N = 25	Over 18 Years N = 18

Medication class	Number prescribed this medication	Number prescribed this medication	Number prescribed this medication

Citalopram	5 (9.1%)	2 (8.0%)	3 (10.0%)

Escitalopram	3 (5.5%)	0 (0.0%)	3 (10.0%)

Fluoxetine	39 (70.9%)	23 (92.0%)	16 (53.3%)

Paroxetine	2 (3.6%)	0 (0.0%)	2 (6.7%)

Sertraline	2 (3.6%)	0 (0.0%)	2 (6.7%)

Mirtazapine	4 (7.3%)	0 (0.0%)	4 (13.5%)

	All N = 15	18 years or younger N = 25	Over 18 Years N = 18

Medicati	Number prescr	Number	Number prescribed this medic


Dependent variable	Independent variables	Odds ratio	CI (95%)	P value

	Adiponectin	0.7	0.33–1.07	0.06

	Age	0.9	0.8–1.1	0.9

 PCOS	WC	0.86	0.74–1.01	0.2

	BMI	1.4	1–1.8	0.3

	25OHD	1.9	1.3–2.5	0.002

Dependent variable	Independent variables	Odds ratio	CI (95%)	P value

	25OHD	1.9	1.3–2.5	0.002


Feature	Control	Treatment	p

Fat necrosis*	2.8±0.3	2.8±0.5	0.791

Inflammatory infiltrate*	3.6±0.1	3.4±0.2	0.247

Interstitial Edema**	4.0 (3.5-4.0)	3.5 (3.5-3.8)	0.382


Age (mean ± SD) years	64.3 (± 3.5)

Gender male/female	12/8

Pre-op logMAR VA (mean ± SD)	1.15 ± 0.88

Post-op logMAR VA (mean ± SD)	0.55 ± 0.30

Lens statusPhakic/IOL	4/16

Duration of detachment (mean ± SD) days	6.25 ± 3.44

Quadrants detached	2.95 (± 0.75)

Location of the main breakSuperior/inferior quadrants	16/4

IOP pre-op	11.7 ± 2.6

IOP post-op	18.9 ± 4.9

IOP 2-hour post-op	16.8 ± 4.7

Age (mean ± SD) years

Gender male/female

Pre-op logMAR VA (mean ± SD)

Post-op logMAR VA (mean ± SD)

Lens statusPhakic/IOL

Duration of detachment (mean ± SD) days

Quadrants detached

Location of the main breakSuperior/inferior quadrants

IOP pre-op

IOP post-op

IOP 2-hour post-op


	Picture name	Related distractor	Unrelated distractor

Animals	Hert (deer)	Konijn	Piano

	Konijn (rabbit)	Hert	Drumstel

	Zwaan (swan)	Geit	Bus

	Geit (goat)	Zwaan	Fluit

Clothing	Jas (jacket)	Hemd	Molen

	Hemd (singlet)	Jas	Tafel

	Rok (skirt)	Trui	Neus

	Trui (sweater)	Rok	Banaan

Transportation	Auto (car)	Bus	Kanon

	Bus (bus)	Auto	Konijn

	Trein (train)	Fiets	Kast

	Fiets (bicycle)	Trein	Trui

Buildings	Kerk (church)	Fabriek	Zwaan

	Fabriek (factory)	Kerk	Zwaard

	Molen (mill)	Kasteel	Dolk

	Kasteel (castle)	Molen	Oor

Weapons	Dolk (dagger)	Zwaard	Arm

	Zwaard (sword)	Dolk	Been

	Kanon (cannon)	Pistool	Bed

	Pistool (gun)	Kanon	Kan

Kitchenware	Kan (pitcher)	Beker	Fabriek

	Beker (cup)	Kan	Pistool

	Bord (plate)	Glas	Rok

	Glas (glass)	Bord	Kerk

Furniture	Bed (bed)	Tafel	Gitaar

	Tafel (table)	Bed	Kasteel

	Bureau (desk)	Kast	Geit

	Kast (wardrobe)	Bureau	Molen

Body parts	Neus (nose)	Arm	Auto

	Arm (arm)	Neus	Peer

	Been (leg)	Oor	Appel

	Oor (ear)	Been	Beker

Fruit	Ananas (pineapple)	Banaan	Hert

	Appel (apple)	Peer	Fiets

	Banaan (banana)	Ananas	Trein

	Peer (pear)	Appel	Hemd

Music instruments	Drumstel (drums)	Gitaar	Bureau

	Gitaar (guitar)	Drumstel	Jas

	Fluit (flute)	Piano	Bord

	Piano (piano)	Fluit	Glas

	Picture name	Related distractor	Unrelated distractor

	Peer (pear)	Appel	Hemd

Music instruments	Drumstel (drums)	Gitaar	Bureau

	Gitaar (guitar)	Drumstel	Jas

	Fluit (flute)	Piano	Bord

	Piano (piano)	Fluit	Glas


Secondary disability	Selection

Difficulties managing daily life	Societal supporta in terms of different forms of housing conditions

Problems at school	Special education (school for children with intellectual development disorders, primary school level)

Psychiatric disorderb	Average cost of depression, bipolar disorder, generalized anxiety disorder and schizophrenia

Alcohol/drug abuse	Alcohol abuse and/or illicit drug use

Suicidal ideation	No separate calculation

Included in other cost references

Criminality	No separate calculation

Cost included in alcohol/drug abuse

Inappropriate sexual behaviour	Not included

Lack of data

Reduced working capacity	Productivity loss for individuals without employment

Mortality	No separate calculation

Cost included in alcohol/drug abuse

Informal caring	Productivity loss for family member/relative/significant other

Secondary disability	Selection

Suicidal ideation	No separate calculation

Included in other cost references

Criminality	No separate calculation

Cost included in alcohol/drug abuse

Inappropriate sexual behaviour	Not included

Lack of data

Reduced working capacity	Productivity loss for individuals without employment

Mortality	No separate calculation

Cost included in alcohol/drug abuse

Informal caring	Productivity loss for family member/relative/significant other


Characteristic	Altitude <1500 m	Altitude >1500 m	p-val

n = 2	n = 397


Animal yields	Advantages	Disadvantages

Milk, Eggs	Easily measurable, almost complete edible	Variation in protein, fat and energy yield, analyses may be useful

Body weight gain	Easily measurable	High portion of non edible fractions in the gains

Carcass weight	Easily measurable	Contains still fractions which are not edible (e.g., bones)

Meat, edible fraction	Completely edible	Categorization and separation not easy

Edible protein	Most important objective of animal production; comparison of various methods and sources to produce protein of animal origin	Categorization of various fractions as edible and difficulties to measure; additional analytical work; variation in N/protein content

Animal yields

Milk, Eggs

Body weight gain

Carcass weight

Meat, edible fraction

Edible protein

Advantages	Disadvantages

Easily measurable, almost complete edible	Variation in protein, fat and energy yield, analyses may be useful

Easily measurable	High portion of non edible fractions in the gains

Easily measurable	Contains still fractions which are not edible (e.g., bones)

Completely edible	Categorization and separation not easy

Most important objective of animal production; comparison of various methods and sources to produce protein of animal origin	Categorization of various fractions as edible and difficulties to measure; additional analytical work; variation in N/protein content


	Number (%)	Mean ± SD	Range

Patient characteristics

Age (year)	52	44.8 ± 14	22–78

Gender

 Male	34

 Female	18

Seizures at presentation	38 (73.1%)

 Antiepileptic drugs	37

 Seizure-free	20

 Recurrent seizure	18

No seizures at presentation	14 (29.9%)

Neurological function (RTOG)	52	1.19 ± 1.15	0–3

 No neurological symptoms	17 (32.7%)

 Minor neurological symptoms	21 (40.4%)

 Moderate neurological symptoms	14 (26.9%)

Professions (n = 52)

 High education	26 (50%)

 Low education	18 (34.6%)

 Retired	8 (15.4%)

Work situation (n = 52)

 Working fully	25 (48%)

 Working half time	11 (21%)

 Not working, due to illness	4 (8%)

 Retired, unrelated to illness	8 (15%)

 Students	2 (4%)

 Unemployed	2 (4%)

Changes in professional situation	19 (36%)

Tumor characteristics

Affected hemisphere

 Right	20 (38.5%)

 Left	31 (38.5%)

 Bilateral	1 (1.9%)

Tumor location	52

Non-eloquent cortex	8

Non-eloquent cortico-subcortical	12

Eloquent cortico-subcortical	32

 Insula	9

 SMAa/Pre SMA	5/2

 Primary somatosensory area	6

 Primary motor area	4

 Language area	6

Tumor volume (cm3)	50	69.3 ± 57.3	2.8–267.8

Smaller (<61 cm3)	24

Larger (>61 cm3)	26

	Number (%)	Mean ± SD	Range

Neurological function (RTOG)	52	1.19 ± 1.15	0–3

No neurological symptoms	17 (32.7%)

Minor neurological symptoms	21 (40.4%)

Moderate neurological symptoms	14 (26.9%)

Professions (n = 52)

High education	26 (50%)

Low education	18 (34.6%)

Retired	8 (15.4%)

Work situation (n = 52)

Working fully	25 (48%)

Working half time	11 (21%)

Not working, due to illness	4 (8%)

Retired, unrelated to illness	8 (15%)

Students	2 (4%)

Unemployed	2 (4%)

Changes in professional situation	19 (36%)

Tumor characteristics

Affected hemisphere

Right	20 (38.5%)

Left	31 (38.5%)

Bilateral	1 (1.9%)

Tumor location	52

Non-eloquent cortex	8

Non-eloquent cortico-subcortical	12

Eloquent cortico-subcortical	32

Insula	9

SMAa/Pre SMA	5/2

Primary somatosensory area	6

Primary motor area	4

Language area	6

Tumor volume (cm3)	50	69.3 ± 57.3	2.8–267.8

Smaller (<61 cm3)	24

Larger (>61 cm3)	26


Symptoms	Frequency	Number	Percentage

Sneezing	No symptoms	1076	69.70%

	Occasional	398	25.80%

	Frequent	69	4.50%

Cough	No symptoms	1380	89.40%

	Occasional	149	9.70%

	Frequent	14	0.90%


Compound	Concentration	Relative activity

(mM)	(%)

dl-threo-β-phenylserine	20	100

d-threo-β-phenylserine	10	0

dl-erythro-β-phenylserine	20	840

dl-threo-(2-thienyl)serine	20	530

(S)-phenylethanol	10	6.9

dl-hydroxynorvaline	20	0

l-threonine	10	0

d-threonine	10	0

l-allo-threonine	10	0

d-allo-threonine	10	0

l-serine	10	0

d-serine	10	0

l-phenylalanine	10	0

d-phenylalanine	10	0

Compound	Concentration	Relative activity

(mM)	(%)

dl-threo-(2-thienyl)serine	20	530

(S)-phenylethanol	10	6.9

dl-hydroxynorvaline	20	0

l-threonine	10	0

d-threonine	10	0

l-allo-threonine	10	0

d-allo-threonine	10	0

l-serine	10	0

d-serine	10	0

l-phenylalanine	10	0

d-phenylalanine	10	0


	Controls	Earthquake victims

Measures	Mean	SD	Mean	SD

ISI	5.05	3.5	6.35	4

IUS-12	35.00	15.2	42.54	16.7

URS total score*	121.03	12.1	128.56	13.3

URS emotional uncertainty*	26.53	6.1	31.69	7.4

URS desire for control	47.22	7.2	46.13	7.7

URS cognitive uncertainty	47.41	8.5	51.10	8.9

STAI*	37.63	8.2	42.46	7.8

BDI	6.54	5.2	8.56	5.8

ASI-3 total score*	10.90	8.3	18.21	13.3

ASI-3 physical concerns	3.41	3.9	5.46	5.6

ASI-3 cognitive concerns*	4.05	3.6	6.77	5.1

ASI-3 social concerns*	3.44	3.4	6.25	5.1

EPQ-R Extraversion/Introversion	9.05	2.8	8.48	3.2

EPQ-R neuroticism*	4.46	2.7	6.33	3.3

EPQ-R psychoticism	3.22	1.9	2.67	1.5

	Controls	Earthquake victims

Measures	Mean	SD	Mean	SD

BDI	6.54	5.2	8.56	5.8

ASI-3 total score*	10.90	8.3	18.21	13.3

ASI-3 physical concerns	3.41	3.9	5.46	5.6

ASI-3 cognitive concerns*	4.05	3.6	6.77	5.1

ASI-3 social concerns*	3.44	3.4	6.25	5.1

EPQ-R Extraversion/Introversion	9.05	2.8	8.48	3.2

EPQ-R neuroticism*	4.46	2.7	6.33	3.3

EPQ-R psychoticism	3.22	1.9	2.67	1.5


Handedness (right (R)/left (L)/ambidextrous (A))	11 R/1A	22R/3L	0.17	6 R/1A	5 R	0.38

Time since onset	589 (588.9) days [3 months, 4 years 11 months]	–	–	527 (647.2) days [3 months, 4 years 11 months]	675 (556.1) days [3 months, 3 years 8 months]	0.69

Normalized volume of overall lesions (mm3)	516.8 (265.2) [30, 982]	–	–	679.6 (160.7) [538, 982]	289 (208.5) [30, 605]	0.005


Clinical Training Programs in	Nation	Commenced

ROMP 	ThailandThe Philippines Malaysia 	2007 (completed) 20092011

DRMP 	The Philippines Thailand 	20102010

NMP 	BangladeshThailand	20102011

Clinical Training Programs in

ROMP

DRMP

NMP

Nation	Commenced

ThailandThe Philippines Malaysia	2007 (completed) 20092011

The Philippines Thailand	20102010

BangladeshThailand	20102011


Absolute power density (mean ± SE, μV2)	Relative power densitya (mean ± SE, %)

Eyes closed	Eyes open	Eyes closed	Eyes open

23.9 ± 3.5*	2.4 ± 0.2	60.8 ± 2.4*	26.0 ± 1.7


Number of familiesb	46

Number of children < 12b	Age (years)

0–3	28

3–6	27

6–12	23

Total	78

Number of children attending Mobile Crèches centerb	0–3	27

3–6	26

6–12	23

Total	76

Average duration of attendance at Mobile Crèches center (child-days per child)c	48

Number of children attending Mobile Crèches centerb	Total	76

Average duration of attendance at Mobile Crèches center (child-days per child)c	48


History	• Activity and employment status

	• Description of LBP

	• Response to previous treatment

	• Co-morbidities and medications

Examination	• Vitals (height, weight, blood pressure)

	• Orthopedic exam (Lasegue, Patrick Fabre, Kemp, Gaenslen, Femoral Nerve Stretch)

	• Neurologic exam (motor, sensory, reflex evaluation)

	• Soft tissue evaluation

Imaging	• X-ray results (obtained if clinically warranted)

	• DEXA results (obtained if clinically warranted)

Biomechanical Assessment	• Torso strength (flexion, extension)

	• Torso endurance (flexion, extension, lateral bridge)

	• Lumbar range of motion (flexion, extension, lateral bending, rotation)

Psychosocial Assessment	• Disability (modified Roland Morris)[32,33]

	• General health status (EuroQol) [34,35]

	• Fear avoidance (Fear Avoidance Beliefs Questionnaire)[36]

	• Kinesiophobia (Tampa Scale of Kinesiophobia)[37]

	• Coping style (Vanderbilt Pain Management Inventory)[38,39]

	• Pain self-efficacy (PSEQ)[40]

	• Depression (CES-D)[41,42]

Preferences	• Which modalities were preferred

	• Expectations for improvement with each modality (5 point scale)

History

Examination

Imaging

Biomechanical Assessment

Psychosocial Assessment

Preferences

• Activity and employment status

• Description of LBP

• Response to previous treatment

• Co-morbidities and medications

• Vitals (height, weight, blood pressure)

• Orthopedic exam (Lasegue, Patrick Fabre, Kemp, Gaenslen, Femoral Nerve Stretch)

• Neurologic exam (motor, sensory, reflex evaluation)

• Soft tissue evaluation

• X-ray results (obtained if clinically warranted)

• DEXA results (obtained if clinically warranted)

• Torso strength (flexion, extension)

• Torso endurance (flexion, extension, lateral bridge)

• Lumbar range of motion (flexion, extension, lateral bending, rotation)

• Disability (modified Roland Morris)[32,33]

• General health status (EuroQol) [34,35]

• Fear avoidance (Fear Avoidance Beliefs Questionnaire)[36]

• Kinesiophobia (Tampa Scale of Kinesiophobia)[37]

• Coping style (Vanderbilt Pain Management Inventory)[38,39]

• Pain self-efficacy (PSEQ)[40]

• Depression (CES-D)[41,42]

• Which modalities were preferred

• Expectations for improvement with each modality (5 point scale)


Serum Adiponectin (μg·ml-1)

Serum HMW Adiponectin (μg·ml-1)

Adiponectin mRNA in Epididymal Fat

PDK4 mRNA in LV

UCP3 mRNA in LV

Serum Glucose (mM)

Serum FFA (mM)

Serum Insulin (ng·ml-1)

Serum Leptin (ng·ml-1)

Serum Triglycerides (mg·ml-1)


	HAQ-Pb		HAQ-Tc

		Relation to the therapist	Satisfaction with therapeutic outcome	Helping alliance		Relation to the patient	Satisfaction with therapeutic outcome	Helping alliance

IIPa	M (SD)	r	r	r		r	r	r

total score	14.92 (3.69)	−0.10	−0.15*	−0.14*		−0.05	− 0.05	−0.06

Domineering/ controlling	8.31 (5.10)	−0.14*	−0.10	− 0.13*		− 0.12	−0.12	− 0.13*

Vindictive/ self-centred	11.02 (5.19)	−0.17**	−0.18**	− 0.19**		− 0.11	−0.11	− 0.12

Cold/ distant	14.79 (6.04)	−0.21*	−0.21**	− 0.23**		− 0.08	−0.08	− 0.09

Socially inhibited	17.93 (6.71)	−0.16*	−0.23**	− 0.22**		− 0.11	−0.11	− 0.12*


	Study population	Respondents	Respondents having consultations concerning sickness certification at least a few times a year

	n	n	% of study population	n	% of the respondents

All	7665	5455	71	4019	74

County

Stockholm	6794	4827	71	3446	71

Östergötland	871	628	72	573	91

Sex

Women	3646	2710	74	2007	74

Men	4019	2745	68	2012	73

Educational level1

Non-specialist		1381		1046	76

Specialist		3995		2947	74

No information		79		26	33

Mean age (years)	48.2	48.3		47.7

	Study population	Respondents	Respondents having consultations concerning sickness certification at least a few times a year

	n	n	% of study population	n	% of the respondents

Stockholm	6794	4827	71	3446	71

Östergötland	871	628	72	573	91

Sex

Women	3646	2710	74	2007	74

Men	4019	2745	68	2012	73

Educational level1

Non-specialist		1381		1046	76

Specialist		3995		2947	74

No information		79		26	33

Mean age (years)	48.2	48.3		47.7


Symptoms (Discomforts)	after 1 ED	after 2 ED	after 3 ED	n

headache	3 (8%)	7 (19%)	3 (8%)	13

light chest pain	-	-	2 (5%)	2

stomachache	-	2 (5%)	5 (14%)	7

excitation	9 (25%)	6 (17%)	8 (22%)	23

anxiety	2 (5%)	-	-	2

shaking hands	-	1 (3%)	4 (11%)	5

somnolence	-	8 (22%)	5 (14%)	13

malaise and others	3 (8%)	9 (25%)	10 (28%)	22

Symptoms (Discomforts)

headache

light chest pain

stomachache

excitation

anxiety

shaking hands

somnolence

malaise and others


 	2009	2004-08	H1N1 Attributable	Rate Ratio: 2009:2004-08

British Columbia

First Nations Reserves	13.77	9.48	4.29	1.45

Other Residents	6.65	6.18	0.47	1.08

Rate Ratio:	2.07	1.53	9.13	1.35*

First Nations:Other

Manitoba

First Nations Reserves	26.84	18.44	8.40	1.46

Other Residents	11.21	10.07	1.14	1.11

Rate Ratio:	2.39	1.83	7.36	1.31*

First Nations:Other

Ontario

First Nations Reserves	16.84	11.74	5.10	1.44

Other Residents	7.35	5.54	1.81	1.33

Rate Ratio:	2.29	2.12	2.81	1.08*

First Nations:Other

	2009	2004-08

British Columbia

First Nations Reserves	13.77	9.48

Other Residents	6.65	6.18

Rate Ratio:	2.07	1.53

First Nations:Other

Manitoba

First Nations Reserves	26.84	18.44

Other Residents	11.21	10.07

Rate Ratio:	2.39	1.83

First Nations:Other

Ontario

First Nations Reserves	16.84	11.74

Other Residents	7.35	5.54

Rate Ratio:	2.29	2.12

First Nations:Other


Color Choice	Volunteer group	p value

HAD normal (n = 460) No. (%) Respondents	HAD anxious (n = 117) No. (%) Respondents	HAD depressed (n = 35) No. (%) Respondents

Positive	212 (46.1%)	39 (33.3%)	8 (22.9%)	Chi-square (4) = 33.656; p < 0.001

Neutral	175 (38.0%)	44 (37.6%)	9 (25.7%)

Negative	73 (15.9%)	34 (29.1%)	18 (51.4%)


Use of CAM/conventional medicine	Frequency (%)

use only CAM	166 (51.1)

use combination of CAM and conventional medicine	159 (48.9)

Total	325 (100)

Use of CAM/conventional medicine

use only CAM

use combination of CAM and conventional medicine

Total


Variable	Year of survey 2005	Year of survey 2012	p

n	%	n	%

nking water					01*

Boiled/Filtered and boiled	61	13.3	48	6.1

Filtered	20	4.4	32	4.1

Chlorinated at home	244	53.3	449	57.5

Mineral	2	0.4	9	1.2

Untreated	131	28.6	243	31.1

Total	458	100	781	100

Destination of trash					0.675

Collection	168	36.4	304	38.8

Buried/Burned/Thrown into river	163	35.4	273	34.8

Thrown in open area	130	28.2	207	26.4

Total	461	100	784	100

Destination of sewage					< 0.001

Septic tank	65	14.2	124	15.6

Cesspit	130	28.4	317	39.8

Open pit	210	46.0	276	34.7

Others	52	11.4	79	9.9

Total	457	100	796	100


Dam	Sire	Family	Contribution	Offspring males	Offspring females	Average weight in g (±se)	Average length in mm (±s.e)	P-value


RV Strain (Origin)	GenBank Accession number

RF (Bovine)	U65924

SA11 (Simian)	M23188

RRV (Simian)	M18736

RV-5 (Human)	M32559

UK (Bovine)	M22306

Gottfried (Porcine)	M33516

OSU (Porcine)	X13190

Wa (Human)	M96825

K8 (Human)	D90269

69M (Human)	M60600

B223 (Bovine)	D13394

H-2 (Equine)	L04638

MDR-13 (Porcine)	L07886

PA169 (Human)	D14724

Lp14 (Ovine)	L11599

EB (Murine)	U08419

993–83 (Bovine)	D16352

L338 (Equine)	D13399

4F (Porcine)	L10359

EHP (Murine)	U08424

Hg18 (Bovine)	AF237665

160/01 (Lapine)	AF526374

A34 (Porcine)	AY174094

TUCH (rhesus macaque)	AY596189

Dhaka6 (Human)	AY773004

134/04 – 15 (Porcine)	DQ061053

CMP034 (Porcine)	DQ534016


	All Subjects	Non-abdominal obesity group	Abdominal obesity group	P

n	326	163	163


	Conditioned taste aversion	Passive avoidance	Morris water maze 19°C	Morris water maze 23°C	Object recognition	Object location

Consolidation	No effect	No effect	No effect	No effect	Effect	Effect

Reconsolidation	Effect	Effect	No effect	No effect	Effect	Effect

Aversive task	+++	+++	++	+	0	0

Spatial task	No	No	Yes	Yes	No	Yes

Associative task	Yes	Yes	Yes	Yes	No	No

	Conditioned taste aversion	Passive avoidance	Morris water maze 19°C	Morris water maze 23°C	Object recognition	Object location

Reconsolidation	Effect	Effect	No effect	No effect	Effect	Effect

Aversive task	+++	+++	++	+	0	0

Spatial task	No	No	Yes	Yes	No	Yes

Associative task	Yes	Yes	Yes	Yes	No	No


	n	Mean age ± SD	T/S ratio ± SD	p*

OA patients	79	69.46 ± 8.97	0.986 ± 0.261	0.684

Healthy controls	166	51.92 ± 18.45	1.008 ± 0.287


Week	Content and homework

1	Browser:	Psychoeducation:

	Information about panic

	Defining goals of training

	Setting up a reward list

	Mobile:	Daily diary

	Registration of current panic event (event-based)

	Daily summary of panic, avoidance, and mood

2	Browser:	Interoceptive exposure:

	Bodily symptoms in panic

	Avoidance

	Safety behaviors

	Mobile:	Respiratory interoceptive exposure exercises

	Daily diary

3	Browser:	In vivo exposure:

	Defining an anxiety hierarchy

	Mobile:	In vivo exposures

	Dizziness interoceptive exposure exercises

	Daily diary

4	Browser:	Cognitive restructuring I:

	Negative automatic thoughts

	Defining anxiety project (training schedule for exposures)

	Mobile:	In vivo exposures

	Further interoceptive exposure exercises

	Daily diary

5	Browser:	Cognitive restructuring II:

	Reality testing of automatic negative thoughts

	Mobile:	In vivo exposures

	Further interoceptive exposure exercises

	Daily diary

6	Browser:	Relapse prevention:

	Early warning signs

	Critical life events

	Evaluation of training and its aims

	Mobile:	Breathing and muscle relaxation exercises

Week	Content and homework

	Daily diary

5	Browser:	Cognitive restructuring II:

	Reality testing of automatic negative thoughts

	Mobile:	In vivo exposures

	Further interoceptive exposure exercises

	Daily diary

6	Browser:	Relapse prevention:

	Early warning signs

	Critical life events

	Evaluation of training and its aims

	Mobile:	Breathing and muscle relaxation exercises


	n	Time to go to sleep n (%)

Before 19:00	Between 19:00 and 21:00	Later

Age group (years)


	F	d.f.	P

Size increase

Sex	4.95	1, 697	0.03

Treatment	0.20	1, 697	0.65

Sex × Treatment	0.60	1, 697	0.44

Weight increase

Sex	4.95	1, 697	0.02

Treatment	0.20	1, 697	0.65

Sex × Treatment	0.60	1, 697	0.44

Development rate

	41.		<


Tissue	Time (Months)	Control	Salmon b	Aimara c

Hair	3	3.4 ± 1.2	6.5 ± 2	242 ± 11 *


Term	Prime number	Relation	Modified Gödel Number

Term1	2

Term2	3	R1: Term2 is a Term1	relation(is a) = 3 × 2 = 6

Term3	5	R2: Term3 is part of Term2	relation(part of) = 5 × 3 × 2 = 30

Term4	7	R3: Term4 is a Term2	relation(is a) = 7 × 3 × 2 = 42


Table 3	All grades	Grade 3

	n	%	n	%

Skin	5	19	1	4

Lymph edema	3	12

Dysphagia	2	8	1	4

Xerostomia	8	31

Loss of taste	4	15

Hearing loss	3	12	2	8

Sinusitis	1	4	1	4

Hypothyreosis	1	4

Hoarseness	1	4

Dry eye	1	4

Skin infection*	1	4	1	4

Trismus	1	4

Table 3	All grades

	n	%

Skin	5	19

Lymph edema	3	12

Dysphagia	2	8

Xerostomia	8	31

Loss of taste	4	15

Hearing loss	3	12

Sinusitis	1	4

Hypothyreosis	1	4

Hoarseness	1	4

Dry eye	1	4

Skin infection*	1	4

Trismus	1	4


Injectable	1071	2.3***	289	1.5	na	na

IUD	560	2.1	na	na	na	na

Totala		3.7		3.6		3.8


Unadjusted OR (95% CI)	Adjusted OR (95% CI)*	Pv


S.n	Criterion	Sensitivity	Specificity	PPV	NPV

1.	Size > 6 cm	0.95	0.57	0.67	0.93

2.	Size >8 cm	0.75	0.76	0.75	0.76

3.	Shape: irregular, lobulated	0.83	0.76	0.76	0.83

4.	Margins: infiltrative	0.91	0.65	0.70	0.89

5.	Isointensity on T1W	0.70	0.76	0.73	0.74

6.	Slight hyperintensity on T2W	0.95	0.38	0.58	0.90

7.	heterogeneous lesion	1	0.5	0.64	1

8.	Peritumoral edema	0.95	0.5	0.63	0.92

9.	Absence of multiplicity	0.54	0.15	0.37	0.26

10.	Intratumoral necrosis	0.87	0.84	0.84	0.88

11.	Intratumoral hemorrhage	0.70	0.65	0.65	0.70

12.	Intratumoral calcification	0.70	0.88	0.85	0.76

13.	Absence of Intratumoral fat	1	0.07	0.5	1

14.	Absence of Intratumoral fibrosis	0.87	0.03	0.45	0.25

15.	Fascia penetration	0.83	0.73	0.82	0.74

16.	Bone changes	0.83	0.84	0.83	0.84

17.	Neurovascular involvement	0.83	0.88	0.86	0.85

18.	Enhancement pattern (Heterogenous)	1	0.07	0.5	1

19.	Absence of T1 hyperintense tracts	1	0.11	0.51	1

20.	Absence of Fluid-fluid levels	0.83	0.26	0.51	0.63

S.n	Criterion	Sensitivity	Specificity	PPV	NPV

1.	Size > 6 cm	0.95	0.57	0.67	0.93

2.	Size >8 cm	0.75	0.76	0.75	0.76

3.	Shape: irregular, lobulated	0.83	0.76	0.76	0.83

4.	Margins: infiltrative	0.91	0.65	0.70	0.89

5.	Isointensity on T1W	0.70	0.76	0.73	0.74

6.	Slight hyperintensity on T2W	0.95	0.38	0.58	0.90

7.	heterogeneous lesion	1	0.5	0.64	1

8.	Peritumoral edema	0.95	0.5	0.63	0.92

9.	Absence of multiplicity	0.54	0.15	0.37	0.26

10.	Intratumoral necrosis	0.87	0.84	0.84	0.88

11.	Intratumoral hemorrhage	0.70	0.65	0.65	0.70

1	Intratu	0.7	0	0

2.	moral calcification	0	.88	.85	0.76

13.	Absence of Intratumoral fat	1	0.07	0.5	1

14.	Absence of Intratumoral fibrosis	0.87	0.03	0.45	0.25

15.	Fascia penetration	0.83	0.73	0.82	0.74

16.	Bone changes	0.83	0.84	0.83	0.84

17.	Neurovascular involvement	0.83	0.88	0.86	0.85

18.	Enhancement pattern (Heterogenous)	1	0.07	0.5	1

19.	Absence of T1 hyperintense tracts	1	0.11	0.51	1

20.	Absence of Fluid-fluid levels	0.83	0.26	0.51	0.63


	WCO	BEO

	Searches	Avg.	Searches	Searches	Avg.	Searches

		Time (s)	per s		Time (s)	per s


Health outcome	Studies exploring associations with weather/climate	Studies projecting the health impacts of climate change

Heat waves	++	+

Other extreme events	+	0

Waterborne and foodborne diseases	++	0

Vectorborne and zoonotic diseases	+	0

Air pollution (limited areas)	++	+

Aeroallergens	+	0

Other health impacts including mental health, nutritional issues related to food security, and population displacement	+	0


 	First assessment, first test (n = 63)	First assessment, second test (n = 63)	P-value for group difference†	Second assessment, first test (n = 61)	Second assessment, second test (n = 61)	P-value for group difference†

Neck flexor muscle endurance test (supine), holding time, sec	36.40 (33.25)	30.92 (25.92)	0.305	34.03 (23.74)	38.10 (33.94)	0.445

Neck flexor muscle endurance test (sitting 45°), holding time, sec	82.33 (57.23)	72.70 (52.83)	0.328	102.11 (82.34)	85.13 (57.81)	0.190

Neck extensor test, holding time, sec	36.21 (25.09)	33.51 (23.56)	0.535	37.02 (28.39)	38.34 (25.72)	0.787

	First assessment, first test (n = 63)	First assessment, second test (n = 63)	P-value for group difference†	Second assessment, first test (n = 61)	Second assessment, second test (n = 61)	P-value for group difference†

Neck flexor muscle endurance test (supine), holding time, sec	36.40 (33.25)	30.92 (25.92)	0.305	34.03 (23.74)	38.10 (33.94)	0.445

Neck fl	82.3	72.7	0.3	102.11 (	85.13 (	0.1

	First assessment, first test (n = 63)	First assessment, second test (n = 63)	P-value for group difference†	Second assessment, first test (n = 61)	Second assessment, second test (n = 61)	P-value for group difference†

exor muscle endurance test (sitting 45°), holding time, sec	3 (57.23)	0 (52.83)	28	82.34)	57.81)	90

Neck extensor test, holding time, sec	36.21 (25.09)	33.51 (23.56)	0.535	37.02 (28.39)	38.34 (25.72)	0.787


Indication

Ischemia/CAD

Myocarditis/CMP

Viability

Stress CMR

Image quality

Good

Moderate

Poor

Complications

None

Mild

Severe

New diagnosis

Therapeutic consequence


	TC (mmol/L)	TG (mmol/L)	HDL (mmol/L)	LDL (mmol/L)

	13.8 ± 0.	1.	3.7 ± 	8


Exposure variablesa\Percentileb	Min

As metabolites (μg g−1 crea)

MMA	0.06

DMA	0.07

iAs	0.11

tAs	0.34


microRNA	Inhibitor Agent	Type of Disease	Investigation Status	Company/Ref

miR-10b	ASO	Glioblastoma	Preclinical	Regulus Therapeutics [108]

miR-21	ASO	HCC, fibrosis	Preclinical	Regulus Therapeutics [109,110]

miR-155	LNA-modified	T cell lymphoma and mycosis fungoides	Phase I	miRagen Therapeutics [111]

miR-221	ASO	Pancreatic carcinoma	Preclinical	Regulus Therapeutics [110]

miR-122	LNA-modified	HCV	Phase II	Santaris Pharma [112,113]

microRNA	Inhibitor Agent	Type of Disease	Investigation Status	Company/Ref

miR-10b	ASO	Glioblastoma	Preclinical	Regulus Therapeutics [108]

miR-21	ASO	HCC, fibrosis	Preclinical	Regulus Therapeutics [109,110]

miR-15	LNA	T cell lymphoma and mycosis fun	Phas	miRage

5	-modified	goides	e I	n Therapeutics [111]

miR-221	ASO	Pancreatic carcinoma	Preclinical	Regulus Therapeutics [110]

miR-122	LNA-modified	HCV	Phase II	Santaris Pharma [112,113]


Evidence code type	Evidence code	Annotation errors	Total annotations	Percentage error rate

Experimental(manually assigned)	EXP	977	5360	18.23

	IDA	12	105764	0.01

	IMP	84	88283	0.10

	IEP	0	10129	0.00

	IPI	0	29877	0.00

	IGI	0	12914	0.00

Computational Analysis(manually assigned)	ISS	85	228605	0.04

	ISO	1	2975	0.03

	ISA	0	5921	0.00

	ISM	0	143	0.00

	IGC	0	483	0.00

	RCA	3	75175	0.00

Author statement(manually assigned)	TAS	4070	46888	8.68

	NAS	3	23578	0.01

Curator statement(manually assigned)	IC	0	5682	0.00

	ND	0	171817	0.00

Automatically Assigned	IEA	639	844441	0.08

Evidence code type	Evidence code	Annotation errors	Total annotations	Percentage error rate

Experimental(manually assigned)	EXP	977	5360	18.23

	IDA	12	105764	0.01

	IMP	84	88283	0.10

	IEP	0	10129	0.00

	IPI	0	29877	0.00

	IGI	0	12914	0.00

Computational Analysis(manually assigned)	ISS	85	228605	0.04

	ISO	1	2975	0.03

	ISA	0	5921	0.00

	ISM	0	143	0.00

	IGC	0	483	0.00

	RCA	3	75175	0.00

Author statement(manually assigned)	TAS	4070	46888	8.68

			2	0.01

	NAS	3	3578

Curator statement(manually assigned)	IC	0	5682	0.00

	ND	0	171817	0.00

Automatically Assigned	IEA	639	844441	0.08


Image	Speed up

Spine (MRI)	32.7%

Chest (X-ray)	33.1%

Fetus (ultrasonic)	52.7%

Head (CT)	53.6%

Image	Speed up

	.7%

Chest (X-ray)	33.1%

Fetus (ultrasonic)	52.7%

Head (CT)	53.6%


Primer target	Primer sequence (5′ to 3′)

Pgc-1α-a F	GCTTGACTGGCGTCATTCG

Pgc-1α-a R	ACAGAGTCTTGGCTGCACATGT

Pgc-1α-b F	GACATGGATGTTGGGATTGTCA

Pgc-1α-b R	ACCAACCAGAGCAGCACATTT

Pgc-1α-c F	AGTGACATGGATGTTGGGATTG

Pgc-1α-c R	GAATGCCTCCGGTTACTCACTT

Pgc-1α4 F	TCACACCAAACCCACAGAAA

Pgc-1α4 R	CTG GAA GAT ATG GCA CAT

FL-Pgc-1αF	TGCCATTGTTAAGACCGA

FL-Pgc-1αR	CCAGAGTCACCAAATGACC

total NT-Pgc-1α F	TGCCATTGTTAAGACCGA

total NT-Pgc-1α R	CCATATCTTCCAGTGACC

total Pgc-1α F	TGATGTGAATGACTTGGATACAGACA

total Pgc-1α R	GCT CAT TGT TGT ACT GGT TGG ATA TG

Primer target	Primer sequence (5′ to 3′)

Pgc-1α-a R	ACAGAGTCTTGGCTGCACATGT

Pgc-1α-b F	GACATGGATGTTGGGATTGTCA

Pgc-1α-b R	ACCAACCAGAGCAGCACATTT

Pgc-1α-c F	AGTGACATGGATGTTGGGATTG

Pgc-1α-c R	GAATGCCTCCGGTTACTCACTT

Pgc-1α4 F	TCACACCAAACCCACAGAAA

Pgc-1α4 R	CTG GAA GAT ATG GCA CAT

FL-Pgc-1αF	TGCCATTGTTAAGACCGA

FL-Pgc-1αR	CCAGAGTCACCAAATGACC

total NT-Pgc-1α F	TGCCATTGTTAAGACCGA

total NT-Pgc-1α R	CCATATCTTCCAGTGACC

total Pgc-1α F	TGATGTGAATGACTTGGATACAGACA

total Pgc-1α R	GCT CAT TGT TGT ACT GGT TGG ATA TG


Variable

Age categories (years)

0–5

6–14

15–45

>45

Gender

Male

Female

Number of household members

1

2

3

4

5

6

>6

Residence

Urban

Rural

Number of sleeping rooms

1

2

3

4

>4

Spraying of rooms with insecticide

No

Yes

Number of children under 5 years

0

1

2

>2

Number of women of child bearing age

0

1

>1

Relationship structure

1 related adult

2 related adults

3+ unrelated adults

Community distribution of malaria medicine

No

Yes

Do not know


Components	Composite Alpha	Extracted variance	Interobserver Reliabilitya	Item	Standb	Var. Error	Factor loadingc	Convergent validityd	Discriminant validity

Component 1	0.79	0.56	84.9	Inflammation	0.59	0.65	0.59	4.64	0.50

Edema	0.74	0.45	0.74	6.11

Pain	0.89	0.21	0.81	6.68

Component 2	0.71	0.55	87.9	Abscess	0.71	0.49	0.78	5.24

Alveolar osteitis	0.78	0.39	0.78	5.74


LVH classification	LVH status	Total population QTd (ms)	p-value	Normotensive group QTd (ms)	p-value	Prehypertensive group QTd (ms)	p-value

Sokolow–Lyon	No LVH	38.77 ± 11.31	0.88	39.11 ± 11.10	0.72	38.33 ± 11.72	0.88


	Study period (weeks)

Time point	3/16	4/16	5/16	6/16	7/16	8/16	9/16	10/16	11/16

Enrolment

 Recruitment	X	X	X	X

 Eligibility screen	X	X	X	X

 Informed consent	X	X	X	X

 Allocation	X	X	X	X

Interventions:

 Discussion group	X	X	X	X	X	X

 Minimal support group (MSG)	X	X	X	X	X	X

 Wait list control group (access to MSG)					X	X	X	X	X

Assessments

 T1	X	X	X	X

 Credibility/expectancy	X	X	X	X	X

 T2			X	X	X

 T3					X	X	X

 Study completion									X

	Study period (weeks)

Time point	3/16	4/16	5/16	6/16	7/16	8/16	9/16	10/16	11/16

Discussion group	X	X	X	X	X	X

Minimal support group (MSG)	X	X	X	X	X	X

Wait list control group (access to MSG)					X	X	X	X	X

Assessments

T1	X	X	X	X

Credibility/expectancy	X	X	X	X	X

T2			X	X	X

T3					X	X	X

Study completion									X


Current year	Next year

Breeders, %	N	Failed breeders, %	N

Breeders	78.9	172	21.1	46

Failed breeders	82.0	50	18.0	11

rrent year	Breeders, %	N	reeders, %

Breeders	78.9	172	21.1	46

Failed breeders	82.0	50	18.0	11


		Medical claims with ICD-9-CM diagnosis codes

Characteristic	Total patients (N = 214)	Schizophrenia only (n = 44)	Bipolar disorder only (n = 162)	Schizophrenia and bipolar disorder (n = 8)


	Mean	SD	Range	Skewa	Kurtosisa

Adolescent self‐worth	26.85	4.53	16–46	−0.47 (−0.46)	3.31 (3.30)

Parent report parent–child closeness	39.09	4.66	21–50	−0.09 (−0.08)	2.75 (2.76)

Parent report expressions of affection	57.35	14.55	23–123	0.41 (0.45)	3.08 (3.34)

	Mean	SD	Range	Skewa	Kurtosisa

Parent report expressions of affection	57.35	14.55	23–123	0.41 (0.45)	3.08 (3.34)


Subthemes	Data extracts

4.1 Lack of empathy with the challenges of medication usage	‘ ... They don't understand that you are wearing stuff on your head that makes you smell like you're painting fences ... it's really frustrating, they [clinicians] need to look at the impact of these treatments, maybe then they could understand why people aren't sticking to them.’ [P11: using topical therapy]

‘My [GP] said, “Well use the coal tar during the day,” and I said, “Well I can't because it's too messy ... ,” and all she said was “Oh, well just wear gloves.” But it's impossible as I'm working with papers all the time.’ [P9: prescribed topical therapy but using herbal therapies]

‘It did kind of put me under a bit of stress, it affected my condition hugely. I really don't understand why [I was unable to be prescribed my preferred biologic], I mean, I try not to think about it too much but at the time it did cause me a lot of worry and upset ... there might have been a very good reason behind it but they didn't want to share it with me.’ [P3: prescribed a biologic]

‘I had to really look [possible side‐effects] up myself on the Internet. She [clinician] was quite blasé about it ... and I was reading all these blogs about side‐effects which worried me, so I wasn't happy that I wasn't getting all the information.’ [P13: using topical and oral therapy]

‘Nobody has ever really asked me how I feel about my psoriasis or how I deal with my psoriasis. Or what my feelings are. Nobody has ever asked me that.’ [P15: using topical therapy and photochemotherapy]

4.2 Lack of support reinforced rejection of psoriasis therapies	‘I stopped going [to the GP] because they weren't helping ... because nothing [treatment] had worked there wasn't really much point in trying another one.’ [P9: prescribed topical therapy but using herbal therapies]

4.1 Lack of empathy with the challenges of medication usage	‘Nobody has ever really asked me how I feel about my psoriasis or how I deal with my psoriasis. Or what my feelings are. Nobody has ever asked me that.’ [P15: using topical therapy and photochemotherapy]

4.2 Lack of support reinforced rejection of psoriasis therapies	‘I stopped going [to the GP] because they weren't helping ... because nothing [treatment] had worked there wasn't really much point in trying another one.’ [P9: prescribed topical therapy but using herbal therapies]


Anatomical region	L/R	Cluster level P(corrected)	Size (voxels)	Voxel level P (FDR-corrected)	Voxel level P (uncorrected)	MNI (mm) x y z	Voxel Z

Limbic lobe uncus	Left	0.015	92	0.232	0.000	−18	2	−22	4.13

Middle Frontal gyrus	Left	0.083	66	0.018	0.000	−18	46	−14	5.21

Cerebellum posterior Lobe	Right	0.025	89	0.125	0.000	26	−34	−40	3.98


Landscape characteristics	Definition

Habitat types

 Floodplain	Open, seasonally flooded grasslands

 Grassland	Open, shrubbed, savannah grasslands

 Acacia woodland	Open woodland with >70% Acacia species

 Riparian woodland	Tall open mixed woodland located in riverine or historic riverine areas

 Mopane woodland	Colophosphermum mopane dominated woodland

Landscape metrics

 Number of habitat patches (NP)	Measure of landscape fragmentation; metric equals the number of patches in the landscape. Value ranges from 1 if one patch covers entire landscape to a maximum equal to the total number of patches

 Landscape mean patch shape index (MSI)	Measure of the average patch complexity within the landscape; metric equals 1 if average patch is square, increasing without limit as shape becomes more irregular

 Index of juxtaposition and interspersion (IJI)	Measure of the intermixing of different habitat patches; probabilistic metric equals 0 if some habitat types are commonly found adjacent to each other but others are rarely found adjacent to each other, ranging to 100 when all habitat types are equally adjacent to all other habitat types


Clinical features	Patients at onset n	Cumulative number of patients at eight years n

Dactylitis	15	24

Nail pitting	10	18

Psoriasis	11	14

Psoriasis-like rash	6	13

Enthesitis	37	41


	Model definition(relevant year in brackets)	External data definition(data source in brackets)

Incidence	OUTCOME: Incidence of first AMI (2010)	Incidence of first AMI since 1998 (linked hospital episodes and mortality statistics, 2010).

Prevalence	Prevalence of ever having had an AMI (2010)	Prevalence of ever having had a doctor-diagnosed AMI (Health Survey for England, 2011).

Remission	Zeroa	Zero

Excess mortality	Excess mortality due to first AMI (2010)	Death where AMI is included anywhere on the death certificate (ONS mortality statistics, 2010).

	Model definition(relevant year in brackets)	External data definition(data source in brackets)

Prevalence	Prevalence of ever having had an AMI (2010)	Prevalence of ever having had a doctor-diagnosed AMI (Health Survey for England, 2011).

Remission	Zeroa	Zero

Excess mortality	Excess mortality due to first AMI (2010)	Death where AMI is included anywhere on the death certificate (ONS mortality statistics, 2010).


Characteristics	Potential patients (n = 10)	Therapists (stage 1) (n = 4)	Therapists (stage 3) (n = 5)

	n	%	n	%	n	%

Sex

 Male	2	20	2	50	2	40

 Female	8	80	2	50	3	60

Age (in years)

 18–30	2	20	0	0	0	0

 30–50	4	40	2	50	3	60

 50–70	4	40	2	50	2	40

Nationality

 British	10	100	4	100	5	100

Highest level of education

 < A-levels	1	10	0	0	0	0

 A-levels	2	20	0	0	0	0

 University degree	5	50	1	25	1	20

 Post-graduate diploma	0		1	25	2	40

 Post-graduate degree	1	10	1	25	1	20

 Doctoral degree	1	10	1	25	1	20

Mental health problem

 Depression	10	100	N/A	N/A

 Anxiety	8	80	N/A	N/A

Previous therapy experience

 None	4	40	N/A	N/A

 Cognitive behavioural therapy	4	40	N/A	N/A

 Mindfulness-based cognitive therapy	3	30	N/A	N/A

 Behavioural activation	1	10	N/A	N/A

 Interpersonal psychotherapy	1	10	N/A	N/A

Area(s) of clinical training

 Cognitive behavioural therapy	N/A		4	100	5	100

 Behavioural activation	N/A		4	100	4	80

 Eye movement desensitisation and reprocessing	N/A		1	25	2	40

 Interpersonal psychotherapy	N/A		1	25	1	20

 Dialectical behaviour therapy	N/A		1	25	1	20

Characteristics	Potential patients (n = 10)	Therapists (stage 1) (n = 4)	Therapists (stage 3) (n = 5)

	n	%	n	%	n	%

us therapy experience

None	4	40	N/A	N/A

Cognitive behavioural therapy	4	40	N/A	N/A

Mindfulness-based cognitive therapy	3	30	N/A	N/A

Behavioural activation	1	10	N/A	N/A

Interpersonal psychotherapy	1	10	N/A	N/A

Area(s) of clinical training

Cognitive behavioural therapy	N/A		4	100	5	100

Behavioural activation	N/A		4	100	4	80

Eye movement desensitisation and reprocessing	N/A		1	25	2	40

Interpersonal psychotherapy	N/A		1	25	1	20

Dialectical behaviour therapy	N/A		1	25	1	20


Gene	Organ	LPS	LPS + HOCbl	P value (versus LPS)

IL	Liver	− 8.30 ± 0.30	−10.6 ± 0.3*	0.0056

	2.70 	2.1


	Limbs = 421

	Mercury	Electronic device


Trait1	No. of records

BW6	511

BW12	511

EP	511

BMP	511

LMP	511


Host	Bacteria	Effective against	Active compound	Reference

Barnacle B. amphitrite	Vibrio, Alteromonas, Alcaligenes, Flavobacterium, and Pseudomonas	Barnacle B. amphitrite	?	Mary et al. (1993)

Algae, sponges, and ascidian Ciona intestinalis	Pseudomonas aurantia, P. citrea, P. piscicida, P. rubra, P. undina, P. ulvae, P. haloplanktis, P. luteoviolacea, P. tunicata, P. nigrifaciens	Polychaeta, Hydroides elegans, barnacle Balanus amphitrite, and ascidian Cliona intestinalis	?	Holmström and Kjelleberg (1999), Holmström et al. (2002)

Nudibranch Archidoris pseudoargus	Pseudomonas sp.	Barnacle Balanus amphitrite	Phenazine-1-carboxylic acid, 2-n-hyptyl quinol-4-one, 1-hydroxyphenazine phenazine-1-carboxylic acid, pyolipic acid	Burgess et al. (2003)

Green alga Ulva reticulata	Vibrio alginolyticus	Polychaeta, Hydroides elegans	Polysaccharide >200 kDa consist of glucose, mannose, galactose, and glucosamine	Dobretsov and Qian (2002), Harder et al. (2004)

Soft coral Dendronephthya sp.	Vibrio sp., uncultured Ruegeria, unidentified a-Proteobacterium	Polychaeta, Hydroides elegans, bryozoan Bugula neritina	?	Dobretsov and Qian (2004)

Sponge Halichondria okadai	Alteromonas sp.	Barnacle B. amphitrite	Ubiquinone	Kon-ya et al. (1995)

Ascidian Stomozoa murrayi	Acinetobacter sp.	Barnacle B. amphitrite	6-bromindole- 3-carbaldehyde	Olguin-Uribe et al. (1997)

Green alga Ulva australis	Pseudoalteromonas tunicata and Phaeobacter sp. strain 2.10	Bryozoan Bugula neritina	?	Rao et al. (2007)

Brown alga Fucus serratus, F. vesiculosus, and the red alga Polysiphonia stricta	Natural communities, Photobacterium halotolerans and Ulvibacter litoralis, Shewanella basaltis, Pseudoalteromonas arctica, Shewanella baltica, and Bacillus foraminis	Barnacle Amphibalanus improvisus	?	Nasrolahi et al. (2012)

Sponge Lissodendoryx isodictyalis	Winogradskyella poriferorum	Polychaete H. elegans and barnacle B. amphitrite	Poly-ether AE	Dash et al. (2009), Dash et al. (2011)


Gene	Forward primer	Backward primer	Size (bp)

GAPDH	GGTCGTATTGGGCGCCTGGTC	TGACGGTGCCATGGAATTTGCCA	148

KIFC1	TCTCTGGGTGGTAGTGCTAAGA	TAAGTCACTTCCTGTTGGCCTG	148

SOX4	GACCGGGACCTGGATTTTAACT	TGAAAACCAGGTTGGAGATGCT	133

PBX2	AAGTTCCAAGAGGAGGCAAACA	TCCTGAGAGATTGAAAGAGCCG	132

ESRRG	GCTATCCTGCAGCTGGTAAAGA	GCTATCCTGCAGCTGGTAAAGA	133

KDM5B	CCCTCAGACACATCCTATTCCG	CAGTCCACCTCATCTCCTTCTG	101

PTGS2	TGTATCCTGCCCTTCTGGTAGA	AAGGAGAATGGTGCTCCAACTT	85

EFNA1	GTGGCAAAATCACTCACAGTCC	CTATGTAGAACCCGCACCTCTG	91

BCL2	AGGATTGTGGCCTTCTTTGAGT	CGGTTCAGGTACTCAGTCATCC	113

SMAD4	TGTTGATGACCTTCGTCGCTTA	ATGCTCTGTCTTGGGTAATCCG	81

PHACTR3	TATGACAGGAGGGCAGACAAAC	GCTTGCTTGATGCATGTACCTC	118

C13orf27	TCAGGCTCAGCAGATGAAATGT	TCCAGTGGATTTTATGGGGAGC	85

PMEPA	CTGAGCCACTACAAGCTGTCTG	CTTCTGAGGACAGGGCATCTTC	85

OXGR1	ATCTTGAGGGTCATTCGGATCG	TGTCGCTGACCACCACATATAG	148

GPNMB	GTCACTGTGATCTCCCTCTTGG	TTTGCACGGTTGAGAAAGACAC	116

Gene	Forward primer	Backward primer	Size (bp)

GAPDH	GGTCGTATTGGGCGCCTGGTC	TGACGGTGCCATGGAATTTGCCA	148

KIFC1	TCTCTGGGTGGTAGTGCTAAGA	TAAGTCACTTCCTGTTGGCCTG	148

	GAC	TGAAA	13

SOX4	CGGGACCTGGATTTTAACT	ACCAGGTTGGAGATGCT	3

PBX2	AAGTTCCAAGAGGAGGCAAACA	TCCTGAGAGATTGAAAGAGCCG	132

ESRRG	GCTATCCTGCAGCTGGTAAAGA	GCTATCCTGCAGCTGGTAAAGA	133

KDM5B	CCCTCAGACACATCCTATTCCG	CAGTCCACCTCATCTCCTTCTG	101

PTGS2	TGTATCCTGCCCTTCTGGTAGA	AAGGAGAATGGTGCTCCAACTT	85

EFNA1	GTGGCAAAATCACTCACAGTCC	CTATGTAGAACCCGCACCTCTG	91

BCL2	AGGATTGTGGCCTTCTTTGAGT	CGGTTCAGGTACTCAGTCATCC	113

SMAD4	TGTTGATGACCTTCGTCGCTTA	ATGCTCTGTCTTGGGTAATCCG	81

PHACTR3	TATGACAGGAGGGCAGACAAAC	GCTTGCTTGATGCATGTACCTC	118

C13orf27	TCAGGCTCAGCAGATGAAATGT	TCCAGTGGATTTTATGGGGAGC	85

PMEPA	CTGAGCCACTACAAGCTGTCTG	CTTCTGAGGACAGGGCATCTTC	85

OXGR1	ATCTTGAGGGTCATTCGGATCG	TGTCGCTGACCACCACATATAG	148

GPNMB	GTCACTGTGATCTCCCTCTTGG	TTTGCACGGTTGAGAAAGACAC	116


Predictors	OR	95% CI	p-Value	Nagelkerke R2

Perceived benefits of HSIV:				0.631

HSIV can prevent children from catching Influenza	2.367	(1.272, 4.404)	0.007

Perceived barriers of HSIV:

The HSIV will cause unknown side effects to children	0.321	(0.149, 0.691)	0.004

Motivating factors of vaccination taking:	3.675	(1.745, 7.742)	0.001

You would be more willing to give your children HSIV shots if the injection was cheap

Predictors	OR	95% CI	p-Value

Perceived benefits of HSIV:

HSIV can prevent children from catching Influenza	2.367	(1.272, 4.404)	0.007

Perceived barriers of HSIV:

The HSIV will cause unknown side effects to children	0.321	(0.149, 0.691)	0.004

Motivating factors of vaccination taking:	3.675	(1.745, 7.742)	0.001

You would be more willing to give your children HSIV shots if the injection was cheap


	Desmopressin (n = 45)	Control (n = 45)	P

Propofol (m		78	0


References	SCI model	Methods	LncRNA expression changes

Animal	Method	Level	Sampling

35	Adult female SD rats (200–250 g)	Contusive spinal cord injury using an NYU impactor (10 g, 12.5 mm)	T10	1, 4 and 7 days post‐SCI	RNA sequencing	1 dpo: 1 down, 6 up4 dpo: 5 down, 2 up7 dpo: 5 down, 2 up

33	Male ICR mice (20–25 g) aged 6–8 weeks	Multicenter Animal Spinal Cord Injury Study (MASCIS) Impactor weight‐drop device(5 g, 25 mm)	T10	1 day, 3 days, 1 week and 3 weeks post‐SCI	Microarray	1 dpo: 181 down, 164 up3 dpo: 290 down, 212 up1 wpo: 565 down, 326 up3 wpo: 40 down, 141 up

34	Adult female SD rats aged 12–14 weeks	Moderate contusion injury	T9	1, 3 and 6 months post‐SCI	RNA sequencing	1mpo: 17 down, 120 up3mpo: 77 down, 162 up6mpo: 54 down, 125 up

References	SCI model	Methods

Animal	Method	Level	Sampling

35	Adult female SD rats (200–250 g)	Contusive spinal cord injury using an NYU impactor (10 g, 12.5 mm)	T10	1, 4 and 7 days post‐SCI	RNA sequencing

33	Male ICR mice (20–25 g) aged 6–8 weeks	Multicenter Animal Spinal Cord Injury Study (MASCIS) Impactor weight‐drop device(5 g, 25 mm)	T10	1 day, 3 days, 1 week and 3 weeks post‐SCI	Microarray

34	Adult female SD rats aged 12–14 weeks	Moderate contusion injury	T9	1, 3 and 6 months post‐SCI	RNA sequencing

LncRNA expression changes

1 dpo: 1 down, 6 up4 dpo: 5 down, 2 up7 dpo: 5 down, 2 up

1 dpo: 181 down, 164 up3 dpo: 290 down, 212 up1 wpo: 565 down, 326 up3 wpo: 40 down, 141 up

1mpo: 17 down, 120 up3mpo: 77 down, 162 up6mpo: 54 down, 125 up


Characteristics of preliminary categories	Final categories	1999/2000	2005	2010

		n	%	n	%	n	%

Permanent work	Non-precarious employment (NP)	575	50.7	739	65.1	859	75.7

 + no or low self-rated risk of future unemployment (regardless of previous unemployment)

Contingent work	Non-precarious employment (NP)	82	7.2	27	2.4	16	1.4

 + no self-rated risk of future unemployment+ no previous unemployment

All others with contingent work AND/OR moderate to high self-rated risk of future unemployment AND/OR previous unemployment	Precarious employment (PE)	416	36.6	306	26.9	207	18.2

Unemployed	Precarious employment (PE)	62	5.5	63	5.6	53	4.7

		1135	100	1135	100	1135	100


	Did not participate Patella lead level	Participated Patella lead level

Characteristic	Low (n = 90)	High (n = 103)	Low (n = 15)	High (n = 16)

Mean age in years ± SD at MRSa	73.0 ± 6.2	78.0 ± 5.9	73.2 ± 4.7	80.7 ± 6.1

Mean years ± SD of education	15.3 ± 2.5	13.2 ± 2.6	16.3 ± 3.1	13.4 ± 2.6

Mean ± SD serum creatinine (mg/dL)	1.1 ± 0.5	1.1 ± 0.3	1.0 ± 0.2	1.2 ± 0.4

Mean ± SD systolic blood pressure (mmHg)	134 ± 16	134 ± 17	133 ± 15	135 ± 20

Diabetes, n (%)	7 (8)	5 (5)	0	1 (6)

Hypertension, n (%)	28 (31)	36 (35)	4 (27)	7 (44)

Taking hypertension medication, n (%)	9 (10)	15 (15)	1 (7)	6 (38)

Myocardial infarction, n (%)	0	6 (6)	0	1 (6)

Stroke, n (%)	0	3 (3)	0	1 (6)

Median (IQR) patella lead (μg/g bone)	10 (6–14)	48 (44–60)	9 (5–15)	63 (43–86)

Median (IQR) tibia lead (μg/g bone)	11 (7–17)	32 (24–41)	13 (9–17)	41 (38–59)

	Did not participate Patella lead level

Characteristic	Low (n = 90)

Mean age in years ± SD at MRSa	73.0 ± 6.2

Mean years ± SD of education	15.3 ± 2.5

Mean ± SD serum creatinine (mg/dL)	1.1 ± 0.5

Mean ± SD systolic blood pressure (mmHg)	134 ± 16

Diabetes, n (%)	7 (8)

Hypertension, n (%)	28 (31)

Taking hypertension medication, n (%)	9 (10)

Myocardial infarction, n (%)	0

Stroke, n (%)	0

Median (IQR) patella lead (μg/g bone)	10 (6–14)

Median (IQR) tibia lead (μg/g bone)	11 (7–17)


Sodium nitrite	Sodium nitrate

Spiked level (μg·g−1)	Recovery (%)	SD	Spiked level (μg·g−1)	Recovery (%)	SD

50	96	13.68	50	96	7.13

100	100	9.64	100	96	16.65

150	98	9.12	150	100	3.28

Sodium nitrite	Sodium nitrate

Spiked level (μg·g−1)	Recovery (%)	SD	Spiked level (μg·g−1)	Recovery (%)	SD

200	101	3.19	200	98	6.76


	Other	Division

Other	935	69

Division	99	3395

FN/1:1	79	39

FP	17	7


Descriptor	SVM	unSVM	Bagging	unBagging	asBagging	PRIFEAB


	N	n female	Age range

Tutor: Medical Doctor	1	0	51

Tutors: CO/AMO	3	0	41 – 65

Tutor: Nurse	1	1	35

Students: First year	3	1	19 – 28

Students: Second year	3	1	22 – 35

Students: Third year	4	1	23 – 30


Predictors	df	AICc	ΔAICc	wi

Δ Latitude of the 80% diversity contour	3	−348.31	0.00	0.65

Δ Eastern U.S. winter temperature	3	−345.14	3.17	0.13

Null	2	−344.74	3.57	0.11

Global temperature anomaly	3	−342.55	5.76	0.04

Northern hemisphere temperature anomaly	3	−342.42	5.88	0.03

Eastern U.S. temperature anomaly	3	−342.42	5.88	0.03


Correction Method	Mean Error before Correction (mm)	Mean Error after Correction (mm)	Standard Deviation before Correction (mm)	Standard Deviation after Correction (mm)

Interpolation	2.737	0.325	2.781	0.549

Function (FFT)	2.737	0.400	2.781	0.581


	Test group*	Active control group*	Total

	N	Mean	SD	N	Mean	SD	N	Mean	SD

Usefulness of

Toothbrushing supplies	61	9.6	1.2	76	9.4	1.8	137	9.5	1.5

Printed postcard messages	54	7.2	3.6

Voice telephone messages	49	6.4	3.9

Overall satisfaction	61	9.5	1.1	76	9.5	0.9	137	9.5	0.9

	Test group*	Active control group*	Total

	N	Mean	SD	N	Mean	SD	N	Mean	SD

Usefulness of

Toothbrushing supplies	61	9.6	1.2	76	9.4	1.8	137	9.5	1.5

Printed postcard messages	54	7.2	3.6

Voice telephone messages	49	6.4	3.9

Overall satis	6	9.5	1.			0.9	13	9.	0.


Old name*	New name*

N.CglI	H.CglI

N.NgoAVII	H.NgoAVII


 Index 	 SS 	 df 	 MS 	 F 	 p

 Pre-tests and post-tests of interaction 	 34.16 	 1 	 17.08 	 0.10 	 0.900

Index	SS	df	MS

Pre-tests and post-tests of interaction	34.16	1	17.08


Anterior wall

 TCC	16,5 μm

 Spectral estimation Burg 	19,5 μm

 Spectral estimation Yule-Walker	21,3 μm

Posterior wall

 TCC	16,5 μm

 Spectral estimation Burg	22,0 μm

 Spectral estimation Yule-Walker	17,0 μm

Anterior wall

Spectral estimation Burg	22,0 μm

Spectral estimation Yule-Walker	17,0 μm